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 All viruses must evade detection by the host immune response to establish productive 
infection. Kaposi’s sarcoma-associated herpesvirus (KSHV) employs numerous sophisticated 
mechanisms that enable it to remain undetected.  The coordinated innate and adaptive immune 
responses suppress KSHV infection and keep the virus in a latent, symbiotic relationship with the 
host. However, loss of immune suppression leads to uncontrolled viral replication, and increased 
potential for KSHV-associated malignancy.  We have uncovered novel mechanisms KSHV utilizes to 
tip the balance of immune control and viral persistence in its favor.  
 Once infection has ensued, KSHV persists in a latent state within a cell. Using latently 
infected cells, KSHV reactivation from latency was shown to occur in response to activation of toll-
like receptors (TLR) 7 and 8. TLRs sense pathogens and induce an inflammatory state to eliminate 
the threat. These results suggest that KSHV senses its environment in response to activation of innate 
immune receptors such as TLRs to initiate viral replication as means of survival.  
 KSHV encodes Orf63, a late lytic protein localized to the tegument of the virion. A role for 
Orf63 in immune modulation was found in blocking NLRP1 and NLRP3 inflamamsomes, two 
members of the NLR family of innate immune sensors and key cellular antipathogen molecules. 
Bioinformatics analyses revealed that Orf63 mimics the nucleotide binding and leucine-rich repeat 
domains of NLRP1, which Orf63 uses to block NLRP1 function. Inhibition of Orf63 expression 
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during primary infection in human monocytes and reactivation in latently infected cells resulted in 
increased cytokine secretion and decreased viral fitness. Hence, viral pathogenesis may be strongly 
affected by NLRs in the absence of Orf63.  
 Proper antiviral adaptive immune responses are dependent on expression of cell surface 
costimulatory molecules on antigen presenting cells. In latently infected monocytes, we found that 
KSHV suppresses expression of costimulatory molecules. Moreover, expression and secretion of 
several proinflammatory cytokines is downregulated in latently infected monocytes compared to 
uninfected control cells. These data suggest that in the latent state KSHV reduces its immunological 
signature and the potential for detection by cells of the adaptive immune response to facilitate 






















 To my grandparents Vito and Joan Sacco, without you I never would have made it to this 
point. Because of you I was able to finish school, which led me further down the road in science and 
to my first job upon graduating college, and where I met my wonderful wife, Stefanie. Thank you 
























 To my advisor, Dr. Blossom Damania, thank you for believing in me when I continuously 
questioned my ability and for giving me the confidence to believe in myself. I am constantly amazed 
at your work ethic, intelligence and enthusiasm day in and day out. It truly is inspiring. I know that 
whenever I needed help your door or inbox were always open. 
 The Damania lab members, both past and present, made lab fun and exciting and a place 
where we can discuss anything from science to sports. Thanks to former lab member Tamara Moyo 
(my “sister”), who was a model for me in how to be a successful graduate student. Thank you to John 
West, my rotation mentor, with whom I enjoyed a sense of normalcy in a world full of pressure, 
expectation and varied personalities. And a special thank you to Patrick Dillon and Aadra Bhatt, two 
friends that I can always rely on for help inside and out of lab.  To Prasanna Bhende for always giving 
objective and sincere advice, I will miss our conversations.  
 I am very grateful to my committee members, Drs. Dirk Dittmer, Mark Heise, Nancy Raab-
Traub and Jenny Ting. You have all been instrumental in my graduate work, which was not limited to 
just committee meetings. Each member influenced me with their support and intelligence, whether it 
was research suggestions, seminars and collaborations all contributed to my success. Also, I want to 
especially thank Mark Heise for his help during the preliminary exam. I know I would not be 
graduating without your support throughout the exam.  



















TABLE OF CONTENTS 
 
LIST OF FIGURES             ix 
LIST OF ABBREVIATIONS            xi 
Chapter One: INTRODUCTION 
 Kaposi’s sarcoma              2 
 Discovery of Kaposi’s sarcoma-associated herpesvirus         5 
 Other KSHV-associated malignancies             6 
 Herpesviridae family of viruses              8 
 Kaposi’s sarcoma-associated herpesvirus           10 
  Transmission           10 
  Epidemiology           10 
  Virion biology           10 
 KSHV lifecycle            11 
  Virus Entry           11 
  Latency           12 
  Lytic lifecycle           13 
  Reactivation from latency         14 
 Innate immunity           14 
  Toll-like receptors          17 
  Nucleotide binding and leucine-rich repeat proteins      18 
vii 
 
  RIG-I-like receptors          24 
  Aim-like-receptors          24 
 Strategies employed by pathogens to inhibit the host innate immune response    26 
  Viral pathogens that modulate NLRs        26 
 Dissertation objectives           28 
 References            30 
 
Chapter Two: TOLL-LIKE RECEPTOR SIGNALING CONTROLS REACTIVATION OF KSHV 
           FROM LATENCY 
 
 Abstract            53 
 Introduction            54 
 Results             56 
 Discussion            78 
 Materials and methods           80 
 Acknowledgments           84 
 References            85 
 
Chapter Three: DISCOVERY OF A VIRAL NLR HOMOLOG THAT INHIBITS THE   
             INFLAMMASOME 
 
 Abstract            92 
 Introduction            93 
 Results             94 
 Discussion          108 
 Materials and methods         129 
 References          135 




Chapter Four: LATENT KSHV INFECTION OF MONOCYTES DOWNREGULATES           
           EXPRESSION OF COSTIMULATORY RECEPTORS OF ADAPTIVE IMMUNITY 
 
 Abstract          140 
 Introduction          141 
 Materials and methods         144 
 Results           148 
 Discussion          160 
 Acknowledgments         162 
 References          163 
 
Chapter Five: GENERAL CONCLUSIONS 
 Conclusions          169 





















LIST OF FIGURES 
Chapter One 
 1. Overview of innate immune signaling                     16 
 
Chapter Two 
 1. TLR stimulation and KSHV reactivation                    58 
 2. TLR7/8, and not TLR4, reactivates latent KSHV                   61 
 3. Single-stranded RNA activates an innate immune response                  65 
 4. Single-stranded poly-U RNA activates KSHV replication                  68 
 5. Whole genome profiling of KSHV after ssPoly-U treatment                  72 
 6. TLR7/8 stimulation mediates KSHV reactivation to single-stranded RNA and VSV           
      infection                                                76 
 
Chapter Three 
 1. Orf63 is a viral homolog and inhibitor of NLRP1                   96 
 2. Orf63 interacts with NLRP1                      99 
 3. Orf63 inhibits NLRP1 inflammasome formation and is necessary for  
     IL-1β inhibition during viral infection       103 
 4. Orf63 inhibits the NLRP3 inflammasome                  106 
 Supplemental 1A. Alignment of KSHV Orf63 with NLRP1                109 
 Supplemental 1B. Alignment of KSHV Orf63 with NLRP1                110 
 Supplemental 2. KSHV Orf63 but not KSHV RTA inhibits NLRP1- 
                            mediated IL-1β secretion      111 
x 
 
 Supplemental 3: Orf63 does not interact with NLRP1 inflammasome              
                components ASC and caspase-1     113 
  
 Supplemental 4: The NBD of NLRP1 is required, but not sufficient, for     
                 interactions with Orf63      114 
  
 Supplemental 5: Orf63-N and Orf63∆N mutants are capable of inhibiting   
    NLRP1 activity       115 
  
 Supplemental 6: Orf63 inhibits the interaction of procaspase-1 with NLRP1and NLRP1     
    oligomerization                   117 
  
 Supplemental 7: NOD2 NBD is required for interactions with Orf63,  
    and Orf63 does not interact with NOD1     119 
  
 Supplemental 8: Purity of primary human monocytes purified from 
    healthy donors        120 
  
 Supplemental 9: Orf63 inhibits IL-1β expression during KSHV  
    reactivation        121 
  
 Supplemental 10: NLRP1 inhibits KSHV reactivation from latency and    
      production of infectious progeny virus     123 
  
 Supplemental 11: Orf63 inhibits NLRP3 in a dose-dependent manner               125 
 Supplemental 12: Orf63 inhibits the NLRP3 inflammasome                126 
 Supplemental 13: Rhesus monkey rhadinovirus (RRV) Orf63 demonstrates   
      homology to NLRP1       128 
 
Chapter Four 
 1: KSHV infection in THP1 cells       149 
 2: KSHV gene expression profile of KSHV-THP-1 cells                 151 
 3: Expression of KSHV LANA by immunofluorescence staining in  
     KSHV-THP-1 compared to uninfected THP-1 cells     154 
  
 4: KSHV-THP-1 cells exhibit reduced CD86 and CD83 costimulatory  
     molecule expression         156 
  
 5: Latent KSHV inhibits expression of costimulatory molecules                157 









LIST OF ABBREVIATIONS 
AIDS  Acquired autoimmune deficiency syndrome 
AIM2  Absent in melanoma 2 
ALR  AIM2-like receptor 
APC  Antigen presenting cell  
ASC  Apoptotic speck-like adaptor protein  
ATP  Adenosine triphosphate 
BCBL  Body cavity based lymphoma 
BHK  Baby hamster kidney 
BIR  Baculovirus inhibition of apoptosis protein repeat domain 
BMDM  Bone-marrow derived macrophage 
BSA  Bovine serum albumin 
CARD   Caspase-activation and recruitment domain 
CD  Castleman’s disase 
CDC  Centers for Disease Control 
CHOP   Cyclophosmide, doxorubicin, vincristine and prednisone 
CIITA  MHC class two transactivator 
cPOP  cellular pyrin-only protein 
CT  Cycle threshold 
CTL  Cytotoxic T cell 
DAMPs Danger-associated molecular pattern 
DAPI  4',6-diamidino-2-phenylindole 
xii 
 
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non- 
  integrin 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
E  Early 
EBV  Epstein-Barr virus 
EMCV  Encephalomyocarditis virus 
FADD  Fas-Associated protein with death domain 
FBS  Fetal bovine serum 
FITC  Fluorescein isothiocyanate 
FLICE  FADD-like interleukin-1 beta-converting enzyme 
FLIP  FLICE inhibitory protein 
GAPDH Glyceraldehyde-3-phosphate-dehydrogenase 
GFP  Green fluorescent protein 
GPCR  G-protein coupled receptor 
HAART Highly active antiretroviral therapy 
HCMV  Human cytomegalovirus 
HDAC  Histone deacetylase 
HHV8  Human herpesvirus 8 
HIV  Human immunodeficiency virus 
HSV  Herpes simplex virus 
HV  Hyaline variant 
IAV  Influenza A virus 
ICAM  Inter-Cellular Adhesion Molecule 1 
IE  Immediate early 
xiii 
 
IFA  Immunofluorescence assay 
IFN  Interferon 
IL  Interleukin 
IRAK  Interleukin-1 receptor-associated kinase 
IRF  Interferon regulatory factor 
KS  Kaposi’s sarcoma 
KSHV  Kaposi’s sarcoma-associated herpesvirus 
L  Late 
LANA  Latency associated nuclear antigenLANA 
LPS  Lipopolysaccharide  
LRR  Leucine-rich receptor 
MAPKK Mitogen-activated protein kinase kinase 
MAVS  Mitochondrial antiviral signaling 
MCD  Multicentric CD 
MHC  Major histocompatibility complex 
MMLV  Moloney murine leukemia virus 
MOI  Multiplicity of infection 
MSM  Men who have sex with men 
MVA  Modified Vaccinia ankara 
MyD88  Myeloid differentiation associated factor 88 
NaB  Sodium Butyrate 
NBD  Nucleotide binding domain 
NFDM  Non-fat dry milk 
NLR  Nucleotide binding and leucine-rich repeat receptor 
NTC  Non-template control 
OAS2  2'-5'-oligoadenylate synthetase 2 
xiv 
 
ORF  Open reading frame 
PAMP  Pathogen-associate molecular pattern 
PAN  Poly-adenylated nuclear RNA 
PC  Plasma cell 
PCR  Polymerase chain reaction 
PEL  Primary effusion lymphoma 
PKR  Double-stranded RNA protein kinase 
PMA  Phorbol myristate acetate 
PRRs  Pattern recognition receptor 
PTLD  Post-transplant lymphproliferative disorder 
PYD  Pyrin domain 
RDA  Representation differential analysis 
RFP  Red fluorescent protein 
RGD  Arginine glycine aspartic acid 
RIP  Receptor interacting protein 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RTA  Replication and transcription activator 
RT-PCR  Real-time PCR 
SDS  Sodium dodecyl sulfate 
STING  Stimulator of interferon genes 
TAB  TAK1-binding proteins 
TAK1  Transforming growth factor β-activating kinase 1 
TBK1  TRAF-family-member-associated NF-kB activator-binding kinase 
TIR  Toll-interluekin-1(IL-1) receptor 
TLR  Toll-like receptor 
xv 
 
TNF  Tumor necrosis factor 
TPA  12-O-tetradecanoylphorbol-13-acetate  
TRAF  tumor necrosis factor associated factors   
TRIF  TIR-domain-containing adaptor protein inducing interferon (IFN-β) 
TRITC  etramethyl Rhodamine Isothiocyanate 
TXNIP  thioredoxin-interacting protein 
VSV  Vesicular stomatitis virus 













































 In 1872, the Austro-Hungarian dermatologist Moritz Kaposi published the first report on 
several clinical cases of middle to late-aged Jewish male patients presenting with skin lesions 
characterized as “idiopathic multiple pigmented sarcoma of the skin” (105). These lesions were found 
mainly on the feet and described as “flat, with a firm elastic consistency, and they are sometimes 
swollen, like a cavernous hemangioma. They stand isolated, and become raised when they enlarge, or 
they cluster and remain more flat”. Kaposi goes on to note that, histologically, cells in the lesion 
cluster and exhibit a yellow-brown to black pigment. The previously uncharacterized disorder would 
later be named Kaposi’s sarcoma (KS), after its discoverer.  It would also take greater than a hundred 
years to discover the etiological agent of the disease, Kaposi’s sarcoma associated herpesvirus 
(KSHV) (40).  
 Once described, it was clear KS was not an immediate public health threat in Europe or North 
America, with only about 600 cases reported in the first half of the twentieth century, and until the 
latter part of the century KS exhibited an incidence rate between 0.02 and 0.06 per 100,000 people 
(132, 179). However, in 1981 an alarming increase in KS among young, homosexual men in New 
York and California signaled the beginning of an epidemic, and what would later be the number one 
killer of patients suffering from another deadly disease, Acquired Immune Deficiency Syndrome 
(AIDS) (35, 65, 88). Also at that time, it was becoming clear that KS was very prevalent in central 
and east Africa, such that levels of KS reached endemic status (19, 189). And with the arrival and 
spread of human immunodeficiency virus (HIV), the etiological agent of AIDS, KS incidence in 
Uganda in 1991, for example, concomitantly rose to 39.3 per 100,000 males and 17.9 per 100,000 
females from 3.6 and 0.2 per 100,000 males and females, respectively, between 1960 and 1971 (153). 
Moreover, childhood KS increased 40-fold during the AIDS epidemic (219). Thus, the arrival of the 
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AIDS epidemic brought about increased awareness of KS and further characterization of the various 
types of KS.  
There are four epidemiological types of KS: classic, endemic, iatrogenic, and AIDS- or 
epidemic-KS. Classic KS is historically a disease that affects elderly men of Mediterranean and 
eastern European descent (105).  This form of the disease is typically a painless disorder, with slow 
developing skin lesions commonly found on the legs (178, 179). Due to the slow nature of classic KS, 
the majority of patients do not need treatment, while spontaneous remission has been documented 
(24). In the rare case when progression does occur, it remains confined to the original lesions. Classic 
KS is not considered a life threatening illness (178, 179).  
The endemic-African form of KS affects HIV-negative hosts including children and is 
typically more aggressive than classic KS (219). There are two subtypes of endemic KS, which are 
divided by geographical, age and pathobiology factors (100). The first subtype resembles classic KS 
in that it is moderately aggressive with localized lesions, however, substantial edema is sometimes 
observed. In addition, in sub-Saharan African countries Uganda, Sudan, Democratic Republic of 
Congo, Rwanda, Burundi, Malawi, Eastern Zaire and the Cameroon coast, adults aged 25-50 years 
old are mostly affected (47, 199). In contrast, the second subtype of KS affects children younger than 
10 years of age of central, eastern and southern Africa. This pediatric form of endemic KS presents as 
a lymphadenopathy and, in general, is considerably more serious than the first type with death 
occurring within two years, and endemic KS is increasing in incidence (76, 205).  
Iatrogenic, or hospital-acquired KS, follows immunosuppression often as a result of treatment 
for solid-organ transplantation, very often after renal transplants (44, 74, 93). Recipients of solid-
organ transplants are up to 1000-times more likely to develop KS compared to healthy controls (70, 
135). Iatrogenic KS develops as a result of immunosuppression and opportunistic infection associated 
with organ transplant. If there is internal organ involvement, the prognosis is considerably poor (157). 
The clinical characteristics of iatrogenic KS are similar to classic KS, and reduction in 
immunosuppression therapy usually results in remission (158).  
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The most severe form is epidemic- or AIDS-associated KS, which, in addition to skin and 
lymph node involvement, may spread to the lungs, gastrointestinal tract, liver or spleen (2). Epidemic 
KS is the leading AIDS-defining malignancy (182). Epidemic KS is most often associated with 
homosexual men in the early 1980s, and as mentioned, more recently with spread of HIV in Africa 
(75). With the introduction of highly active antiretroviral therapy (HAART), KS incidence dropped 
precipitously in the late 1990s, which is attributable to reconstitution of the host immune system that 
is otherwise suppressed by active HIV infection (3, 34, 61, 62, 198). With increased life-span 
attributed to HAART, there is accumulating evidence demonstrating higher incidence of non-AIDS-
defining cancers such as Hodgkin’s lymphoma, lung cancer, hepatocellular carcinoma, and breast 
cancer found among HIV infected people (182). However, KS still remains the most frequent 
malignancy in the HIV positive in the USA and in many parts of Africa, KS is the most common 
cancer in the entire population (31). 
KS lesions are composed of multiple cell types including inflammatory mononuclear cell 
infiltrate, however, KS is defined by a classic spindle-shaped lymphatic endothelial cell, or so called 
spindle cell (45). KS lesions are multifocal and exhibit marked neovasculature with irregularly shaped 
endothelium-lined vascular spaces. The tumor is generally polyclonal at early stages, but evolution to 
a monoclonal neoplasia has been documented (163).  
 
Discovery of Kaposi’s sarcoma-associated herpesvirus (KSHV) 
 The AIDS-epidemic and concomitant sharp rise in incidence raised awareness of KS and, 
although researchers suspected an infectious etiological agent for KS for decades, it was not until 
1994 that the true agent would be discovered. However, it is worth mentioning a brief history of the 
suspected etiological agents. Indeed, 30 years prior it was suggested that KS may be of viral origin 
(148). Moreover, extensive research was done in the 1970s and 1980s to show that KS was viral in 
etiology, with evidence for a human herpesvirus, cytomegalovirus (HCMV), being found in KS 
lesions (81-87, 151, 153).  However, this work never convincingly demonstrated an etiological role 
 5 
 
for CMV, only that it was often, but not always, found in these lesions. A little bit later, and after 
many unsuccessful attempts to identify the causative agent, a clue would come from an 
epidemiological study conducted by Beral and colleagues at the Centers for Disease Control (CDC) 
(18). Beral’s epidemiological study of homosexual and bisexual AIDS patients demonstrated a 20-
fold higher KS incidence compared to immunosuppressed hemophilic men, and although it did not 
identify the infectious agent, the study provided support for an infectious cofactor in the development 
of KS other than human immunodeficiency virus and enabled continued research into the true cause 
of KS. Because attempts to culture the infectious agent had failed, researchers were becoming 
convinced an HIV factor, specifically the tat protein, may be a reason for development or progression 
of KS in HIV-1 infected people since Tat-depleted conditioned media blocked development and 
growth of AIDS-KS endothelial cells (68). In addition, various other non-culturable agents such as 
bacteria and papillomaviruses were suspected to be cofactors (138). Then, several years later, two 
researchers, Patrick Moore and Yuan Chang, using a newly developed method to identify differences 
between two complex genomes called representational differential analysis (RDA), showed that 25 of 
27 KS lesions contained viral DNA sequences similar to but unique enough from other human 
herpesviruses to warrant the classification of a new human virus, KSHV (40, 124).  Still, KSHV as an 
etiological agent of KS may not have completely satisfied Koch’s postulates for disease etiology 
since like other human viruses, KSHV cannot be experimentally, and ethically, introduced into 
humans, shown to cause disease, and subsequently isolated from lesions (174). Instead, KSHV 
satisfies an alternate criteria consisting of strength of association, consistency, and experimental 
evidence among other factors to show that manipulation of KSHV alters KS outcome (180). Strong 
evidence was presented by Whitby and colleagues showing that HIV patients later developed KS 
(209).  Additionally, other groups isolated  KSHV from B-cell lymphomas, which is consistent with 
other gammaherpesviruses, and isolation of KSHV DNA from endothelial cells of KS tumors all 
conclusively demonstrated that KSHV was the causative agent of KS and a new member of the 
herpesvirus family (8, 22, 36, 209).  
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Other KSHV-associated malignancies  
 KSHV is commonly associated with two B cell disorders: multicentric Castleman’s disease 
(MCD) and primary effusion lymphoma (PEL) or body cavity-based lymphoma (BCBL). First noted 
in 1956 by Benjamin Castleman, Castleman’s disease (CD) was described as a unicentric proliferative 
tumor of the lymphatic system, which is a mild disorder requiring minimal treatment (33). CD is 
characterized by three variants: hyaline vascular (HV), plasma cell (PC), or a mixed HV/PC type (77, 
110). HV CD is generally benign in nature, however, MCD and specifically PC MCD is highly 
aggressive with patients demonstrating enlarged lymph nodes, endothelial cell proliferation, and 
associated with high fatality generally from autoimmune hemolytic anemia or secondary cancer. 
Although MCD is considered to be a polyclonal plasmablast of an immature phenotype originating 
from naïve B-cells, monoclonal populations of PC MCD have been observed (92, 164). HIV positive 
patients with MCD are nearly always coinfected with KSHV versus 50% KSHV positive for HIV 
negative MCD patients (60, 192). High levels of interleukin-6 (IL-6), a cytokine inducing B-cell 
proliferation and differentiation, were associated with MCD, and indeed treatment with anti-IL-6 
antibody showed a positive effect (15, 146, 149). It is worth noting that KSHV itself expresses a viral 
homolog of human IL-6, vIL-6, which suggests a dependence on this cytokine and supported by 
therapeutic treatment with anti-IL-6 antibodies (137). Treatment of KSHV-associated MCD with 
ganciclovir, a viral replication inhibitor, is very effective suggesting lytic replication is necessary for 
disease progression (32). Conventional chemotherapy as well as treatment with anti-CD20 antibody 
are also moderately effective in the setting of MCD (145, 150). 
 The other B-cell disorder universally associated with KSHV is PEL, a monoclonal lymphoma 
found in body cavities including the pericardium, pleurum, and peritoneum that arises in the context 
of an immunodeficiency such as in AIDS or elderly patients (29, 36, 207). Thus, PEL and MCD 
represent two different tumors in that PEL arose from clonal outgrowth of malignant B cells whereas 
MCD is considered a polyclonal hyperplasia. Both MCD PC and PEL are severe disorders with poor 
prognosis, with PEL patient survival between 2 and 6 months (114). Cyclophosphomide, doxorubicin, 
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vincristine and prednisone (CHOP) is the current first-line therapy for PEL, however only 43% of 
patients demonstrate brief remission (188).  Recent therapeutic efforts have yielded positive results 
based on molecular analyses of the pathways upon which PEL depends, for example 
phosphatidylinositol 3-kinase-Akt-mTOR signaling pathway, or based on providing antiviral drugs at 
the same time as viral replication inhibitors (20, 113). However, since PEL is relatively rare, analysis 
of clinical responses to these regimens is limited.  
 
Herpesviridae Family of Viruses 
 By the end of the twentieth century, it was becoming increasingly clear that KS in both HIV-
negative and HIV-positive individuals was likely because of an infectious agent (18, 148). The 
discovery of KSHV in 90% of AIDS-associated KS by Drs. Yuan Chang and Patrick Moore in the 
mid-1990s was the penultimate event in a long line of studies to find the etiological agent of KS. 
Their seminal finding as well as follow-up studies demonstrated that DNA isolated from an AIDS-
related lymphoma that was continuously infected showed that the DNA did not hybridize to other 
herpesvirus’ DNA including EBV or CMV (139). However, sequence analysis confirmed that the 
new agent belonged to the herpesvirus family of human DNA tumor viruses, and would now be 
classified as the 8
th
 human herpesvirus or HHV8. 
 The Herpesviridae family includes over 200 unique viruses, which have been found in nearly 
every species of animal, and in humans herpesviruses are associated with numerous diseases. The 
human herpesviruses are further subdivided into the alpha-, beta-, and gamma-herpesviruses (156). 
The alphaherpesvirus subfamily includes Herpes Simplex virus types 1 and 2 (HSV-1 and HSV-2) 
and Varicella Zoster virus (VZV). Both HSV and VZV cause several diseases in humans. After 
mucosal or genital contact, HSV-1 and HSV-2 respectively, establish infection in the dorsal root 
ganglia or trigeminal ganglia (156). Replication of the virus at mucosal surfaces results in vesicular 
lesions.  HSV is associated with oral and genital herpes, which are generally self-limiting diseases but 
because they are so common are a significant public health concern (133, 213). HSV-1 infection can 
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lead to development of keratitis, a disease of the cornea that can result in corneal scarring and 
blindness, and in rare cases HSV-1 infection can lead to meningitis (133). VZV causes varicella or 
chickenpox upon infection and replication in the skin (156). Later in life, latent VZV can reactivate 
resulting in shingles, which can cause severe pain and long-term debilitation (152). The 
betaherpesvirus members include cytomegalovirus (CMV), Roseolovirus (HHV-6) and HHV-7. CMV 
infection is an asymptomatic infection, however, CMV mononucleosis occurs in rare cases (156).  
Congenital CMV infection is a serious disorder of newborns that damages the central nervous system 
and is thought to be the number one cause of sensorineural deafness and brain damage in the US 
(154). Roseolovirus and HHV-7 are sometimes associated with Exanthem subitum, which is an 
infantile disease normally resulting in fever and systemic rash (30). Finally, the human 
gammaherpesviruses include EBV (HHV-4) and KSHV (HHV-8). EBV is primarily associated with 
infectious mononucleosis as well as several malignancies such as nasopharyngeal carcinoma, post-
transplant lymphoproliferative disease (PTLD), Burkitt’s lymphoma and Hodgkin’s lymphoma (51, 
186, 200). It is important to note that these malignancies are often found in the context of immune 
suppression, and other herpesvirus diseases often develop in this context.  
 Herpesviruses were originally defined based on a shared viral molecular structure consisting 
of an icosahedral capsid containing linear double-stranded DNA with a virus-derived glycoprotein 
spiked envelope surrounding a proteinacious tegument layer that surrounds the capsid. Herpesviruses 
are similar in several biological properties (156). First, each herpesvirus expresses a large number of 
enzymes that modulate host processes such as nucleic acid metabolism, and DNA and protein 
synthesis. Next, all herpesvirus viral DNA and capsid assembly takes place within the nucleus with 
further modification occurring in the cytoplasm during egress. Third, herpesviruses progeny virus 
production is a lytic process, with lysis of the cell always taking place. Finally, productive infection 
results in the establishment of a latent state in the viruses’ natural host, allowing life-long persistent 
infection. In contrast, herpesviruses differ widely in their cellular tropism, replication kinetics as well 




Kaposi’s Sarcoma-Associated Herpesvirus 
Transmission 
 Transmission of KSHV was originally thought be sexual in nature since KSHV was detected 
much more frequently in men who have sex with men (MSM) compared to other HIV-associated 
diseases and KSHV was detected in semen and the female genital tract (18, 28, 56, 211). Moreover, 
KSHV prevalence was higher in persons infected with STDs as well as correlated with number of 
sexual partners in homosexual men (109, 129). Nevertheless, detection of high levels of KSHV in 
saliva of MSM compared to semen, lack of heterosexual sexual transmission, as well as evidence that 
KSHV infection in children in endemic areas suggested that KSHV was not definitively a STD (63, 
80, 130, 155, 190, 210, 215).  Thus, KSHV infection is most likely transmitted via infected saliva 
consistent with horizontal transmission and can also be transmitted by infected blood used in 
transfusions (11). Several cofactors are likely to influence transmission including geographical and 
environmental differences, exposure to water-born parasites as well as host genetic factors (64, 131, 
176, 185, 204). 
Epidemiology  
 KSHV is globally distributed with a low seroprevalence in the general population, 
particularly in developed nations; however, in Africa and Mediterranean regions KSHV is endemic. 
In the U.S., KSHV is detected anywhere from 0 to 23% with a more likely estimate in the range of 0 
to 10% (78, 96, 109, 123). However, in the MSM population in the U.S, KSHV positivity rises to 50-
60%.  Detection is heavily influenced by the methodology since different immunological assays are 
subject to false positives or have high stringencies (67). In sub-Saharan Africa, incidence of KSHV 
ranges from 12.5% to as high as 82% with considerable geographical variation, with the high 
prevalence correlated with the AIDS epidemic (46, 66, 78, 94, 206). In contrast, KSHV prevalence is 





  KSHV is a linear double-stranded DNA virus, like all herpesviruses, of about 165Kb, which 
encodes for greater than 80 open reading frames as well as several virally encoded micro-RNAs (27, 
121, 161). The KSHV genome is flanked by multiple tandem repeats of GC-rich DNA (121). There 
are regions of homology between herpesviruses with large blocks of conserved genes, but many 
regions of genes unique to KSHV are found, which are designated with a K in their nomenclature 
e.g., K1 and K15. KSHV DNA is encapsidated by a icosahedral capsid containing 162 capsomeres 
surrounded by a proteinacious layer called the tegument, which incorporates viral proteins into the 
virion for structural purposes, but also for release during infection for modulating host protein 
synthesis, immune responses and initiating viral gene expression (140, 141). The outer-most layer of 
the virion consists of viral glycoproteins and host derived double-membrane lipid bilayer (10, 69, 




KSHV establishes productive infection in a variety of cell types, including B cells, 
monocytes, endothelial cells, plasmacytoid and conventional dendritic cells, keratinocytes and 
epithelial cells, which indicate that KSHV likely has broad tropism in vivo (37, 208). However, 
KSHV-infected PEL cells from patient biopsies are the only naturally derived cell lines for use in 
vitro. Initial cellular adsorption has been shown to be facilitated by heparan sulfate (HS), which likely 
serves as an attachment factor in this process and may explain the wide tropism of the virus due the 
ubiquitous expression of HS (6, 21). Once initial attachment is aided by HS, several putative 
receptors are thought to mediate entry. Most notably, integrins αVβ5, α3β1, and αVβ3 are important 
in infection of endothelial cells, although complete inhibition of KSHV was not observed when all 
integrin types were blocked (5, 143, 203). KSHV glycoprotein gB protein possesses a RGD (Arg-
Gly-Asp) motif, which is often required for interactions between integrins, suggesting multiple 
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integrins likely mediate entry (37). Two additional surface receptors were shown to play a role in 
KSHV entry: the 12-transmembrane glutamate/cysteine exchange transporter protein xCT in adherent 
cells, and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin 
(DC-SIGN) in dendritic cells, macrophages and B cells (103, 168, 169). However, none of these 
receptors are complete in mediating entry and it is likely additional receptors facilitate entry, and 
these are likely to be cell specific, thus giving KSHV the ability to infect multiple cell types.  
 Once KSHV has initiated the infectious process, it most likely continues into the cell through 
endocytosis. Several lines of evidence suggests this is the case in B cells, monocytes, fibroblasts, 
epithelial cells and endothelial cells (4, 6, 90, 99, 165, 166, 169). Once inside the endosome, the viral 
envelop fuses with the lipid membrane of endocytic vesicles, releasing the viral capsid and tegument 
proteins into the cytoplasm (37). From there, assisted by dynein motors, KSHV is trafficked down 
microtubules to nuclear membrane pores, through which the viral DNA is released into the nucleus 
and initiation of viral gene expression occurs. Infection is associated with concomitant induction of 
cellular gene expression, which is thought to be manipulation on behalf of the virus to facilitate 
infection (187).  
Latency  
 After primary infection of naïve cells, viral DNA is released into the nucleus at which time a 
period of viral replication may ensue, though, in most instances the viral genome is circularized to 
form an episome and initiation of the dormant phase. Within several days, the episomal viral DNA 
has become attached to host chromosomes through the viral protein latency-associated nuclear 
antigen (LANA) (48). LANA is one of several transcripts that can be detected during latency, which 
include viral cyclin (vCyclin), viral fas-associated death domain (FADD)-like interleukin-1β-
converting enzyme (vFLIP), viral interferon regulatory factors 1 and 3 (vIRF1 and vIRF3), Kaposin, 
as well as several viral microRNAs (16, 41, 108, 126, 184, 216). These proteins modulate the immune 
response to latently infected cells and promote cell growth (115). LANA attaches to the viral DNA 
through the terminal repeats and to the host DNA through H2A-H2B histone linkage (12, 79). This 
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facilitates replication of viral DNA during cellular DNA replication and transmission to daughter cells 
after mitosis.  
Lytic Lifecycle 
 Lytic replication proceeds through temporal regulation of gene transcription in three distinct 
stages: immediate early (IE), early (E) and late (L) transcription. Interestingly, a single protein or lytic 
switch protein, replication and transcription activator (RTA/Orf50), is responsible for initiation of 
lytic replication (89). Thus, RTA is the earliest detected transcript in lytically replicating cells and as 
its name indicates RTA activates immediate early gene transcription through an N-terminal DNA-
binding domain and C-terminal transactivation domain that binds RTA-responsive elements in viral 
promoters (191). Signals that activate RTA are key to determining what governs reactivation and viral 
replication.  
 IE proteins are characterized by transcription in the presence of cycloheximide, which 
inhibits protein synthesis. Very few IE proteins are known and, like RTA, mainly serve as 
transactivators of E genes, including Orf45, Orf50, and K8 (120, 183). Orf45, however, has 
immunomodulatory capabilities in that it inhibits IRF-7-dependent induction of type I interferon 
through blocking IRF-7 phosphorylation and nuclear translocation (218).  
 The next stage in lytic replication is the transcription of E genes, which are defined by their 
susceptibility to cycloheximide treatment and not dependent on viral DNA synthesis. Most E proteins 
serve to facilitate viral DNA replication. These include a thymidine kinase, DNA polymerase, 
ribonucleotide reductase, and various DNA binding proteins. A key E protein is KSHV Orf57 which 
plays a critical role in blocking RNA splicing, nuclear-cytoplasmic transport of unspliced RNA, and 
mRNA polyadenylation (128). Once E gene products have been synthesized to sufficient levels, DNA 
replication begins at two sites of origin of replication (ori-lyt) in a rolling circle mechanism at 
replication complexes in the nucleus. This process requires binding by ori-specific DNA binding 
protein and viral DNA polymerase, primase, helicase, and DNA binding proteins.  
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 Transcription of L genes begins once DNA replication is underway, as demonstrated by 
inhibitors of viral lytic DNA synthesis such as ganciclovir. L proteins are generally virus structural 
proteins of the capsid and envelope as well as proteins localized to the tegument. Accumulation of L 
proteins begins the process of assembly of progeny capsids within the nucleus. Newly formed capsids 
move out of the nucleus and acquire viral proteins of the tegument and finally the glycoprotein 
studded lipid envelope is wrapped around the tegument and capsid. At this point, mature progeny 
virions lyse the cells during release from the infected cells, subsequently capable of repeating the 
infectious process in a naive cell.  
Reactivation from Latency 
 In vivo, reactivation from latency is required for life-long viral persistence and transmission. 
In cultured PEL cells, a small percentage (1-5%) of cells will undergo spontaneous reactivation from 
latency. Reactivation can be initiated by several chemical stimuli including 12-O-
tetradecanoylphorbol-13-acetate (TPA), histone deacetylase (HDAC) inhibitors and biologically 
relevant stimuli hypoxia, interferon-γ, and hormones epinephrine/norepinephrine (38, 39, 53, 214). In 
addition, superinfection with KSHV or coinfection with different viruses such as CMV or HIV 
initiates reactivation from latency.  It is possible that a common pathway is required or reactivation 
may occur in response to different triggers through unique pathways. The molecular mechanisms of 
KSHV reactivation in several of these settings remain incompletely characterized. 
 
Innate Immunity 
 The immune system is composed of the innate and adaptive immune responses that work in 
concert to protect the host and prohibit infection from harmful pathogens, yet at the same time permit 
commensal bacterial relationships. Initial recognition of invading pathogens is facilitated by cellular 
receptors of the innate immune response. Through which signal transduction cascades are triggered 
leading to the transcriptional upregulation of cytokines and chemokines and a cellular and organismal 
anti-pathogen state. The innate immune response occurs within minutes to hours of the initial 
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pathogenic event. The adaptive or acquired immune response is a delayed mechanism, occurring 
between 7-10 days post-infection, consisting of cell proliferation and somatic gene editing to tailor 
the immune response to a particular pathogen. Effector molecules upregulated by the innate response 
play a necessary role in shaping adaptive immunity in strength, duration, cell type involvement, 
specificity and trafficking to sites of infection. B and T cell receptors undergo a process of receptor 
editing, or honing, to ensure that B and T cells effectively recognize pathogen-derived peptides on the 
surface of antigen presenting cells (APCs), which are activated by the innate immune response, to 
eliminate the pathogenic threat. Hence, the innate immune response is critical in being able to sense 
the pathogen, containing the infection through immediate release of antipathogen effector molecules, 
as well as initiate the adaptive immune response.  
The innate immune system is composed of several families of germline-encoded pattern 
recognition receptors (PRRs), which recognize pathogen-associate molecular patterns (PAMPs) such 
as nucleic acids, lipids, and proteins unique to bacteria, viruses and fungi (107). PRRs are found on 
nearly every cell type in both peripheral and lymphoid tissues, but are highly expressed in APCs 
monocytes, macrophage, dendritic cells and B cells. There are three main families of PRRs: Toll-like 
receptors (TLRs), Retinoic acid-like receptors (RIG-I), and the nucleotide binding and 
oligomerization, leucine-rich repeat family (NLRs). More recently, a new class of intracellular 














Figure 1: Overview of innate immune signaling. Depicted are families of innate immune sensors 
and their cognate ligands. TLR and cytoplasmic sensors RIG-I and MDA-5 as well as NLRs NOD1 
and NOD2 (not pictured) upregulate expression of proinflammatory cytokines including proIL-1β, 
which is trafficked to the cytoplasm and cleaved by active caspase-1 to generate the biologically 
active form of IL-1β. After sensing their cognate antigen, NLRs activate procaspase-1 subsequent to 












There are 10 functional TLRs in humans, and they can be found on the surface or located 
within the endosome of APCs. The toll family was discovered in Drosophila and found to be capable 
of mediating immune responses to fungus (122). Later, toll homologs would be found in mammalian 
cells and shown to be vital in innate immunity (134). TLRs are single transmembrane proteins 
consisting of a leucine-rich repeat (LRR) domain, which is found on the outside of a cell, or within 
the endosome. The LRR domain is responsible for binding PAMPs and facilitates heterotypic 
interactions between different TLRs. TLRs 1, 2, 4, 5, and 6 are found on the cell surface and detect 
PAMPs such as bacterial and fungal cell wall constituents lipopolysaccharide (LPS), peptidoglycan, 
and bacterial flagellum, while endosomal TLRs 3, 7, 8, and 9 generally detect virally derived single-
stranded or double-stranded RNA and DNA (106).  
Recognition of each TLR by its cognate ligand initiates a signal transduction cascade 
beginning with a toll-interleukin-1(IL-1) receptor (TIR) domain located on the cytoplasmic side of the 
cellular or endosomal membranes. Next, downstream TLR signaling is facilitated by interactions 
between the TIR domain and the adaptor protein myeloid differentiation associated factor eighty-
eight (MyD88) (23). TLR3 exclusively and TLR4 occasionally utilize another adaptor protein called 
TIR-domain-containing adaptor protein inducing interferon (IFN-β) (TRIF). MyD88 signaling 
converges on one of IL-1 receptor associated kinases (IRAKs) including IRAK1, 2, or 6, to which a 
variety of tumor necrosis factor associated factors (TRAFs) are associated, facilitating signal 
transduction. Various IRAK-TRAF associations determine the downstream transcription factor that is 
activated in response to TLR signaling. For instance, IRAKs 2 and 4 communicate to TRAF6 to 
activate mitogen activated protein kinase kinase (MAPKK), through which p38 and JNK activation 
induces ATF2/CREB and JUN/AP-1 phosphorylation, respectively, leading to translocation of these 
transcription factors to the nucleus and upregulation of proinflammatory cytokines. IRAK1 activates 
TRAF 6, which either directly signals phosphorylation of IKKα or activates transforming growth 
factor β-activating kinase 1 (TAK1) and TAK1-binding proteins 2 and 3 (TAB 2 and 3) to activate 
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NF-kB. Phosphorylated IKKα in turn phosphorylates interferon regulatory factor 7 (IRF 7), causing 
IRF-7 to homodimerize and translocate to the nucleus to upregulate type I IFN expression. In 
addition, downstream of TLR4, TRAF3 associates with the kinase IKKε and TRAF-family-member-
associated NF-kB activator-binding kinase (TBK1) to phosphorylate IRF7 and IRF3, which 
heterodimerize and regulate IFN gene expression. TLR 3 and 4 signaling through TRIF leads to the 
association of receptor interacting protein (RIP) and eventual activation of canonical p50/p65 NF-kB 
pathways and upregulation of NF-kB inducible cytokines. Thus, each TLR is capable of signaling to 
IRF or NF-kB transcription factors through related pathways and ultimately modulate expression of 
host antipathogen genes.  
 
Nucleotide-binding, oligomerization and leucine-rich repeat proteins 
Recent research has uncovered an emerging role for the NLR family of innate immune 
sensors in various human diseases from metabolic disorders, cancer, autoinflammatory conditions and 
autoimmune disease (52). The association with human disease suggests that dysregulation of innate 
immunity is a key factor in disease progression. 
There are over 22 genes encoding for NLRs in humans, most of which remain 
uncharacterized. The original NLR discovered was class II transactivator (CIITA), a transcriptional 
regulator of major histocompatibility class II (MHCII) molecules, and the only known nuclear and 
transcriptional regulatory NLR. CIITA is associated with bare lymphocyte syndrome, a disorder in 
which there is a deficiency in MHCII and ultimately results in defective immune responses and death 
from opportunistic pathogens (127). NLRs are structurally related to resistance R proteins in plants 
that detect pathogen avirulence gene products through cognate R protein interactions, which serves to 
limit infection (43). NLRs and R proteins contain an N-terminal effector domain that serves to 
facilitate homotypic protein-protein interactions with various adaptor proteins or directly with 
enzymes such as procaspase-1. Typically, these effector domains are a pyrin (PYD) or caspase-
activation and recruitment domain (CARD), however, it can also include a baculovirus inhibition of 
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apoptosis protein repeat domain (BIR). Adenosine triphosphate (ATP) is necessary for the molecular 
oligomerization exhibited by NLRs, and as a result, they are characterized by a centrally located 
nucleotide-binding domain (NBD). The last feature of the NLR family is a variable number of LRRs, 
which is considered to function in ligand sensing and negative regulation in the inactivated state.  
With the exception of CIITA, NLR function is hypothesized to be sensing PAMPs and, more 
recently, danger associated molecular patterns (DAMPs) as well as environmental irritants. Similar to 
TLRs, NLRs such as NOD1 and NOD2 interact with RIP2 to activate the transcription factors IRFs 3 
and 7, NF-kB and MAPK and the eventual upregulation of IL-6, TNF, pro-IL-1β and pro-IL-18 as 
well as antiviral type I IFN. Moreover, several NLRs such as NLRX1 and NLRC5 can inhibit NF-kB 
and type I IFN signaling, suggesting this pathway has evolved mechanisms to regulate its pathways 
for control of the innate immune response. Still other NLR family members regulate innate immunity 
through the formation of large molecular complexes called inflammasomes.  
Inflammasomes, by definition, are responsible for generation of biologically active IL-1β and 
IL-18. IL-1β and IL-18 are capable of mediating infection and activation of NF-kB through secretion 
and binding to their cognate receptors, IL-1 (IL-1R) and IL-18 (IL-18R). Inflammasomes generally 
consist of oligomerization of a particular NLR, recruitment of procaspase-1 and apoptotic-associated 
speck-like protein containing a CARD domain (ASC). To date, several NLR family members have 
been shown to form inflammasomes including NLRP1, 3, NLRC4 and, more recently, several non-
NLR PRRs have been shown to form inflammasomes and therefore active IL-1β and IL-18. These 
include absent in melanoma 2 (AIM2) and retinoic acid inducible gene-I (RIG-I).  
Inflammasome activation has been shown to occur in response to many PAMPS, DAMPS, 
and environmental triggers; however, direct ligand binding to the LRR has not been proven and 
whether NLRs directly sense specific motifs is uncertain. Despite the paucity of data showing a 
biochemical mechanism of direct ligand recognition, it is clear that inflammasomes are necessary for 
the innate immune response and maintaining homeostatic balance. Although bacterial and fungal 
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pathogens activate NLRs, only a description of the viral activators of inflammasomes is highlighted 
below.  
The most well characterized inflammasome is the NLRP3 inflammasome, which consists of 
six to seven molecules of NLRP3, ASC and procaspase-1. In response to PAMPS, NLRP3 self 
oligomerizes and associates with ASC through PYD-PYD interactions, and ASC with procaspase-1 
through CARD-CARD interactions. The first viral activator of the NLRP3 inflammasome was Sendai 
virus (SeV) and influenza A virus (IAV) (104). Using macrophages deficient in NLRP3, infection 
with SeV or IAV resulted in loss of detection of the p20 subunit of caspase-1 indicating that NLRP3 
played a role in sensing SeV and IAV leading to caspase-1 activation and IL-1β. Later, a role for 
NLRP3 in sensing IAV infection in vivo would be confirmed by showing that mice lacking NLRP3 
had higher mortality and  reduced IL-1β and that NLRP3 inflammasome dependent responses were 
critical for development and proliferation of CD4, CD8 T cells and mucosal and systemic IgG 
immune responses (7, 97). It is important to note that activation of NLRP3 was attributed to 
generation of reactive oxygen species (ROS) in response to viral infection, suggesting that, since IAV 
also activates TLRs 7 and 8, NLRP3 may respond secondarily to infection and not necessarily to a 
viral PAMP itself. In this regard, it is hypothesized that NLRs may sense intracellular changes in 
response to viral infection such as generation of ROS through free thioredoxin-interacting protein 
(TXNIP) interacting with NLRP3, or cathepsin B in response to lysosomal disruption after 
phagocytosis, or finally it is hypothesized that membrane pore formation resulting in K+ efflux leads 
to PAMP influx and activation of NLRP3 (7, 160, 217). It remains to be seen whether one or all 
models activate inflammasomes, however, recently it was described that the IAV M2 protein, which 
forms a proton ion channel, activated NLRP3 alone and suggests that ionic disturbances is indeed the 
mechanism by which NLRP3 is activated in response to IAV infection (98). NLRP3 is activated by 
another RNA virus, encephalomyocarditis virus (EMCV), in combination with another cytoplasmic 
sensor MDA-5, suggesting inflammasomes and RLRs work together in limiting EMCV infection and 
opens up the possibility that in response to other viral infections, multiple innate immune sensors 
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likely regulate host immunity (162). The NLRP3 inflammasome mediates innate immunity to two 
DNA viruses in addition to the RNA viruses described, including adenovirus and modified Vaccinia 
Ankara (MVA). THP-1 acute monocytic leukemia cells treated with shRNAs to knockdown NLRP3 
showed a significant reduction in IL-1β in response to MVA infection, and cross-talk between TLRs 
2 and 6 again suggest multiple sensors of the innate immune system contribute to the host response to 
viral infection (54). This was confirmed using NLRP3
-/-
 bone-marrow derived macrophages 
(BMDM). Adenovirus is a non-enveloped DNA virus, as opposed to MVA, which is an enveloped 
DNA virus. Adenovirus was shown to activate IL-1β processing and secretion in THP1 cells, and that 
this was dependent on the viral DNA itself (142). Using NLRP3 deficient peritoneal macrophages, 
adenoviral infection-induced IL-1β maturation was significantly inhibited, and later NLRP3 was 
shown to induce immunity to adenovirus in vivo albeit a complete reduction was not observed 
indicating additional, redundant sensor for adenovirus infection likely exist. This is not surprising 
given that multiple sensors are known to recognize a single virus. However, more recently, an 
NLRP3-independent role was described for adenoviral infection, and instead, β3-integrins were 
suggested to be the key pathway in activation of proinflammatory responses irrespective of DNA 
sensing (55) while two additional reports indicates NLRP3 is necessary (13, 14). Herpesviruses, like 
MVA, are a family of large, enveloped DNA viruses, which establish lifelong latent infection in the 
human host. Varicella-zoster virus (VZV) is the etiological agent of chickenpox (varicella) and 
shingles (herpes zoster). In THP1 cells, melanoma cells, and skin xenografts, the NLRP3 
inflammasome was induced after VZV infection resulting in recruitment of ASC and caspase-1 (147).  
 NLRC5 is ubiquitously expressed and its highest levels are detected in brain, lung and 
prostate with lower levels detected in spleen, lymph nodes, and thymus. It contains an N-terminus 
CARD domain, and central NBD and LRR domains. In human foreskin fibroblasts (HFFs) infected 
with HCMV, NLRC5 is significantly upregulated and was shown to be moderately dependent on the 
upregulation of IFN-γ (116). NLRC5 regulates expression of IL-6, TNF, CXCL10, type I IFN, and 
CCL3 and 5, and knockdown of NLRC5 during HCMV infection resulted in reduced IFN-alpha 
 21 
 
expression suggesting it may play a role in antiviral responses to herpesviruses. At the same time, 
another report emerged suggesting NLRC5 sensed SeV in THP1 cells and primary human dermal 
fibroblasts, suggesting NLRC5 was capable of innate immunity to RNA and DNA viruses, similar to 
NLRP3 (144). It remains unclear whether both NLRs sense PAMPs specific to viral infection or a 
secondary event such as ROS generation or ion imbalance. Treatment of NLRC5 deficient bone 
marrow derived dendritic cells, macrophages and peritoneal exudate cells with activators of various 
inflammasomes did not alter IL-1β processing and secretion, suggesting NLRC5 may have a unique 
activator and does not play a role in the activation of other inflammasomes (117). Still others have 
described a negative regulatory role for NLRC5 in response to viral infection. NLRC5, in response to 
LPS treatment interacts with IKKα and IKKβ to inhibit phosphorylation and NF-kB activation (50). 
Alternatively, knockdown of NLRC5 resulted in increased innate immune responses, specifically, 
RIG-I and MDA-5 were activated in NLRC5’s absence. Benko and colleagues also identified NLRC5 
as a negative regulator of innate immune responses in over-expression studies in HEK293T cells, 
with NF-kB, AP-1, and type I IFN signaling suppressed (17). Moreover, they found that suppression 
of NLRC5 leads to upregulation of TNF, IL-6, and IL-1β.  It remains to be seen what effect activation 
of NLRC5 has in vivo in response to HCMV and SeV and whether these conflicting reports are due to 
cell type specificity or inflammasome versus non-inflammasome function.  
 NOD2 interacts with RIPK2 via homotypic CARD-CARD interactions, ultimately leading to 
NF-kB nuclear translocation and upregulation of IL-6 and TNF-α. NOD2 stimulation can also 
activate MAPKs p38, ERK and JNK, which is important for both innate and adaptive immune 
responses. Unsurprisingly, NOD2 has recently emerged as an important cellular factor in combating 
viral infections from respiratory syncytial virus (RSV), IAV, parainfluenza virus 3, and vesicular 
stomatitis virus (VSV). In primary normal human bronchial epithelial cells,  macrophages and 
embryonic fibroblasts, RSV, VSV as well as H1N1 IAV infection upregulated NOD2 expression, 
which was necessary for IFN-β expression (177). Interestingly, infection relocalized NOD2 to the 
mitochondria where it interacted with mitochondria antiviral signaling protein (MAVS). The 
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interaction between MAVS and NOD2 was dependent on the LRR and NBD domain of NOD2, 
which is somewhat counter intuitive considering both molecules contain CARD domains, and that 
MAVS interacts with RIG-I through CARD-CARD interactions. Nevertheless, this study firmly 
established two distinct roles for NOD2, first in response to bacterial ligands NOD2 activates NF-kB 
and proinflammatory pathways, whereas activation by viral infection leads to signaling through 
MAVS and an antiviral response consisting of type I IFN induction. This work established discrete 
roles for NLRs in antiviral immunity and suggests that in different contexts, NLRs will act differently 
to tailor the host response to the invading pathogen. In support of a role for NOD2 in antiviral 
immunity, Dugan et al, demonstrated that NOD2 interacted with 2’-5’-oligoadenylate synthetase type 
2 (OAS2), which is important in recognition and elimination of many viral infections through RNase 
L-mediate degradation of viral RNA (59).  
Given that NOD2 relocates to the mitochondrial membrane to associate with MAVS during 
viral infection, the discovery of a mitochondrial located NLR seemed logical; however, the newly 
discovered NLRX1 is hypothesized to be a negative regulator of antiviral signaling due to the fact it 
lacks any effector signaling domain. Overexpression of NLRX1 led to interaction with MAVS and 
subsequently blocked RLR-dependent NF-kB and type I IFN responses. Infection of HEK293T cells 
with SeV in the presence of siRNA targeting NLRX1 resulted in a marked increase in antiviral 
responses, demonstrating that NLRX1 serves to dampen the host response to viral infection (136). 
Shortly after the initial description of NLRX1, Arnoult et. al., described an opposing role for NLRX1 
in that through localization to mitochondrial matrix it upregulated ROS production and NF-kB and 
JNK signaling (9). In addition, NLRX1-dependent production of ROS after treatment with Chlamydia 
trachomatis was recently described (1). The production of ROS is thought to activate inflammasomes, 
in which case NLRX1 would positively regulate NLR function; however, since NLRs appear to play 
multiple roles it is possible that NLRX1 could negatively regulate type I IFN responses through 




Rig-I-Like Receptors  
While RLRs have been shown to mediate antiviral immune responses to many viruses, here 
we will describe recent reports suggesting a novel role for RLRs, specifically RIG-I, in formation of 
an inflammasome-like structure and, by definition, production of IL-1β and IL-18. Formation of 
inflammasomes as defined by recruitment of procaspase-1 and production IL-1β and IL-18 has been 
expanded to include non-NLR innate immune sensors.  In addition, RIG-I associates with NLR 
family member NOD2, indicating that relationships between innate immune molecule families is 
important for host immunity. WT BMDMs infected with VSV demonstrate significant IL-1β 
secretion, however, RIG-I deficient BMDM show no IL-1β secretion (162). Furthermore, VSV 
infection induced the proteolytic processing of procaspase-1 to caspase-1 as determined by 
immunoblotting for the p10 subunit of caspase-1. The production of pro-IL-1β was found to be 
dependent on MAVS, CARD9 and BCL-10. Interestingly, RIG-I associated with ASC to activate 
caspase-1 and production of active IL-1β, independently of NLRP3. MDA-5, a RLR family member, 
did not form an inflammasome after infection with VSV or ECMV, a known activator of MDA-5. 
Another group found that RIG-I signaling lead to secreted active IL-1β and IL-18 after infection with 
IAV, which was dependent on caspase-1 (173). Thus, RIG-I has the potential to activate NF-kB, type 
I IFN and inflammasome innate immune responses. It is important to note that activation of 
cytoplasmic antiviral responses may depend on the production of cathepsin B since it was shown that 
in the absence of cathepsin B, inflammasome formation was inhibited following EMCV and VSV 
infection, although a direct connection to RIG-I was not demonstrated (172). Thus, while RIG-I 
activation may proceed in response to viral ligands, inflammasome formation, presumably RIG-I and 
other inflammasomes, may be dependent on lysosomal disruption and cathepsin release as a general 







Several groups identified a novel cytoplasmic sensor capable of detecting dsDNA (197). An 
interferon inducible 200 (IFI200/HIN200) family member, called absent in melanoma two (AIM2) 
was found to recruit ASC and procaspase-1 to form an inflammasome in response to Vaccinia virus, 
murine cytomegalovirus (MCMV), and various bacteria (26, 72, 73, 95, 102, 170, 175). The IFI200 
family consists of four members in humans (IFI16, MNDA, IFX and AIM2). Importantly, IFI200 
family members have N-terminal PYD domains, which facilitate interactions with the adaptor protein 
ASC. AIM2 binds DNA through the HIN-200 domain, thus confirming its ability to sense 
cytoplasmic DNA. In mice lacking AIM2, MCMV titers were higher than WT mice, and this was 
correlated with increased pyroptosis, a caspase-1-dependent cell death process. The function of AIM2 
in inflammasome activation is entirely independent of traditional antiviral responses including type I 
IFN as well as independent of NLR inflammasomes. However, AIM2, in coordination with stimulator 
of interferon genes (STING), is capable of inducing type I IFN responses through TBK1 and IRF3 
activation.  
Another member of the IFI200 family, IFI16, also plays a role in detection of viral DNA 
since it was found to associate with Vaccinia DNA. It was clear from investigations on AIM2 
function that AIM2 was not a universal sensor of viral DNA since viruses such as HSV-1 did not 
activate AIM2. However, a role for STING was clear. Thus, it was found that IFI16, through the 
adaptor protein STING, mediated type I IFN, CXL10, IL-6, and TNF expression after HSV-1 
infection. A role for IFI16 in inflammasome activation was not established (202). Additional studies 
further established a role for IFI16 in interferon induction (58). Thus, it appears that IFI200 family 
members are capable of differential innate immunity roles. Given that IFI200 family members contain 
a PYD domain, it remains to be determined whether specific activators of these sensors result in 
activation of an inflammasome or IFN signaling depending on the agonist. IFI16 can be nucleolar, 
nucleoplasmic, cytoplasmic or membrane associated and most IFI200 members are differentially 
spliced and regulate expression of a number of cellular genes (125). Since IFI16 senses cytoplasmic 
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DNA, one could speculate it may also be important for detection of nuclear DNA, either viral or 
cellular. HCMV ppUL83 protein utilizes IFI16 for initiation of viral transcription (49). Thus, the 
nuclear and cytoplasmic localization of IFI16 may determine its role in either host immunity or 
transcriptional regulation.  
 
Strategies Employed by Pathogens to Inhibit Host Innate Immune Response 
As cellular sensors are discovered and their mechanisms of host immunity elucidated, so too 
are pathogenic inhibitors capable of blocking these sensors. As host immunity has evolved to counter 
the ever-present threat of infection, pathogens have co-evolved to counter this response. In some 
cases, multiple inhibitors of a pathway are necessary for infection. With the emerging importance of 
NLRs in pathogen sensing, recent work has focused on uncovering pathogen-encoded inhibitors of 
the NLR response. Indeed, several viral encoded inhibitors are known to inhibit various 
inflammasomes at multiple levels, and bacterial inhibitors have also been characterized. The 
discovery of pathogenic inhibitors of NLRs underscores the importance of this arm of the host 
immune response in combating infection.  
 
Viral Pathogens that Modulate NLRs 
DNA viruses like poxviruses and herpesviruses have large genomic coding capacities, and are 
known to express viral homologs of cellular proteins, which serve diverse functions including 
inhibiting host immunity, apoptosis, promoting cell proliferation, blocking differentiation and cell 
migration.  
Often, viral inhibitors mimic cellular proteins in function. For instance, PYD-only proteins 
(cPOP) are cellular proteins that negatively regulate inflammasome formation through disruption of 
ASC with NLRs (196). The first virally-encoded homolog discovered to have the potential to inhibit 
NLRs was found in myxoma virus (MxV), a poxvirus family member that causes disease in rabbits. 
The MxV protein M013 was shown to bind ASC similarly to the cellular POP proteins (101). Loss of 
 26 
 
M013 results in a severely attenuated virus with reduced replication in monoctyes and lymphocytes 
with increased active caspase-1 and secreted IL-1β. Similarly, another poxvirus, Shope fibroma virus, 
expresses a viral POP, gp013L, that colocalized and associated with ASC (57).  In HEK293 cells 
overexpressing NLRP3 inflammasome components, gp013L inhibited secreted IL-1β.  
The first inhibitor described was a Cowpox protein crmA. CrmA blocks caspase-1 by directly 
interacting with and preventing proteolytic processing of procaspase-1 to active caspase-1, resulting 
in reduced IL-1β secretion (171). In the absence of crmA, poxvirus lesions in chicken allantoic 
membranes were decreased, however, in vivo there was no difference in IL-1β levels, suggesting 
additional mechanisms exist to suppress caspase-1 or IL-1β. Cellular serpin proteinase inhibitor 9 (PI-
9) blocks pro-caspase-1 processing to attenuate inflammation, therefore, poxviruses seem to have 
taken advantage of this cellular mechanism of attenuation for their advantage. Indeed, several other 
poxvirus encoded serpins would be characterized. Vaccinia virus gene B13R encodes a protein 
homologous to crmA, SPI-2, that blocks IL-1β processing in THP1 cells, but is dispensable for viral 
infection in vivo (111, 112). Myxoma virus also encodes a caspase-1 inhibitor, Serp2, which when 
deleted, results in attenuation of the virus in vivo. Serp2 cannot compliment a crmA deleted  Cowpox 
virus, suggesting crmA is more important for viral infection (159, 201). Since poxviruses express a 
wide variety of cellular homologs, it therefore is not surprising that they also express IL-1β and IL-18 
scavenger receptors (vIL-1βR/18R) capable of blocking signaling of their respective cellular 
homologs. This also suggests that redundancies in blocking specific antiviral pathways are important 
and that a deficiency in one viral inhibitor that shows little to no effect on viral fitness or 
inflammation should not be surprising (57, 112, 159, 167, 171, 201). It is worth noting that cellular 
BCL-2 and BCL-xl, two antiapoptotic proteins, have been shown to inhibit the NLRP1 
inflammasome (25, 71). Vaccina and other viruses such as herpesviruses encode viral homologs of 
BCL-2 family members (25, 118, 119, 181).  Hence, it remains to be seen whether these proteins play 
a role in blocking the NLRP1 inflammasome.  
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Additional viruses have been shown to encode inhibitors of inflammasome sensors. H1N1 
IAV protein NS1 inhibits the export of host mRNA as well as block innate immunity. NS1 contains a 
RNA-binding and dimerization domain, which when mutated, induced significantly more active IL-
1β and IL-18 compared to control virus (195). Increased inflammation resulted in apoptosis in 
macrophages, most likely due to caspase-1 dependent cell death since caspase-1 levels were elevated 
in the absence of NS1. However, since NS1 has many other roles in innate immune response 
pathways, it is likely that type I IFN as well as other inflammatory cytokines induced by the NS1 
target double-stranded protein kinase receptor (PKR) contributed to apoptosis (91). This result points 
to the significance of NS1 in inflammasome signaling, and based on extensive work showing IAV 
activates inflammasomes, the relationship between IAV and NLRs is likely to be important in better 
understanding pathogenesis and disease.  
 
Dissertation Objectives: 
1) Determine the effect of TLR stimulation on the KSHV lifecycle 
KSHV establishes life-long latency in the host. Hence, this virus is able to evade the innate 
immune response during primary infection.  We hypothesized that TLR activation of the host innate 
immune response upon secondary infection of a latently KSHV-infected cell could result in either 
dampening of the innate immune response to the incoming secondary pathogen or reactivation of the 
virus from latency. In this objective, we proposed to investigate whether TLR activation reactivated 
KSHV from latency. 
2) Characterize the role of Orf63 in inhibiting NLR innate immune responses 
NLRs are a family of receptors similar to TLRs in the ability to detect and eliminate invading 
pathogens. NLRs activate caspase-1 and the inflammasome-associated proinflammatory cytokines, 
IL-1β and IL-18, and several NLRs mediate upregulation of type I interferon and additional 
cytokines. Pathogen detection results in the formation of multimeric structures called inflammasomes 
composed of a specific NLR, caspase-1 and apoptotic-associated speck-like protein (ASC).  We have 
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discovered a novel viral homolog of cellular NLRP1 encoded by KSHV called Orf63. We 
hypothesize that Orf63 is a virulence protein that promotes KSHV survival through inhibition of 
NLRP1 innate immune signaling. 
3) Evaluate the effect of KSHV latency on immune response costimulatory molecules in 
monocytes 
KSHV is able to persist within the human host by evading the detection mechanisms of the 
immune system. KSHV infection in vivo has been found in antigen presenting cells of the immune 
system such as monocytes, which are involved in recognition of viral infection and initiation of an 
adaptive immune response. We hypothesize that infection of monocytes by KSHV will result in 
suppression of immune response activation markers or costimulatory molecules including CD1a, 
CD80, CD83, and CD86. Furthermore, we hypothesize that several cytokines important for an 
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 Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s 
sarcoma, primary effusion lymphoma (PEL) and multicentric Castleman’s disease. Like other 
herpesviruses, KSHV establishes life-long latency in the human host with intermittent periods of 
reactivation. Physiological triggers of herpesviral reactivation are poorly defined.   Toll-like receptors 
(TLRs) recognize pathogens and are vital for the host innate immune response. We screened multiple 
TLR agonists for their ability to initiate KSHV replication in latently infected PEL. Agonists specific 
for TLR7/8 reactivated latent KSHV and induced viral lytic gene transcription and replication.  
Furthermore, vesicular stomatitis virus (VSV), a bonafide physiological activator of TLR7/8, also 
reactivated KSHV from latency.  This demonstrates that secondary pathogen infection of latently-
infected cells can reactivate KSHV. Human herpesviruses establish life-long latency in the host and it 
is plausible that a latently-infected cell will encounter multiple pathogens during its lifetime, and that 
these encounters lead to episodic reactivation.  Our findings have broad implications for physiological 




 Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) is a member of the 
gammaherpesviridae (13, 48). KSHV is the etiological agent of Kaposi’s sarcoma (KS), the most 
common AIDS-associated malignancy, and is causally linked to two B cell lymphoproliferative 
disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) (1, 13, 
48). All herpesviruses, including KSHV, exhibit both latent and lytic phases during their lifecycle. B 
lymphocytes are the primary latent reservoir of KSHV, although KSHV can persist latently in 
multiple cell types (5, 39, 57). KSHV reactivates and replicates in response to chemical compounds 
such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA/PMA) or butyrate (40, 43). Demethylation of 
the promoter for the KSHV replication and transcription activator (RTA), and activation of the 
protein kinase C pathways occur in response to treatment with these agents. 
 Toll-like receptors (TLRs) mediate innate immunity and recognize molecular patterns unique 
to pathogens eg. bacteria, fungi or viruses (2, 53). Several TLRs reside within endosomes and can 
recognize either RNA (TLRs 3, 7 and 8) or DNA (TLR9) (4, 7). The TLR pathway can also be 
activated by endogenous host stimuli such as components of dying cells (34). Thus, cellular RNA 
released from apoptotic or necrotic cells can activate TLR7 and TLR8 as well (31). PEL are 
considered post-germinal center B cells (10, 23). Normal germinal center B cells express TLR1, as 
well as TLR6 through TLR10 (8). Therefore, endosomal TLRs constitute the majority of TLRs 
expressed in B cells, and the TLRs expressed in PEL were hitherto unknown. 
 TLR activation stimulates the transcription of interferon regulatory factors (IRF) and NF-κB 
transcription factors. We have previously reported that KSHV infection of monocytes leads to the 
upregulation of TLR3 and its downstream targets, IFN-β1 and CXCL10 (56). Moreover, TLR4 has 
been shown to mediate innate immune responses against KSHV in endothelial cells (32).   
A central question regarding the KSHV viral lifecycle relates to the physiological trigger that 
governs the switch from viral latency to lytic replication. We hypothesized that during its lifetime, a 
KSHV latently-infected B cell would encounter additional secondary pathogens or other stimuli, eg. 
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nucleic acids released from necrotic cells, which would trigger TLR signaling in latently infected 
cells. We speculated that these would be physiological triggers for viral reactivation of KSHV from 
latency.  
 To test this hypothesis, we screened several latently infected PEL cell lines with agonists 
specific for different human TLRs. Stimulation of KSHV latently infected B lymphocytes with the 
TLR8 ligand, single-stranded polyuridine (ssPoly-U), a synthetic ssRNA homolog, strongly 
reactivated KSHV from latency.  Stimulation with synthetic TLR7 ligands also reactivated the virus, 
albeit to a lesser extent than ssPoly-U. To test the hypothesis that TLR7/8 activation resulted in 
authentic viral reactivation, we analyzed KSHV transcription in four different PEL cell lines that were 
stimulated with TLR7/8 ligands. In all cases TLR7/8 activation triggered the signature lytic 
reactivation pattern of transcription. In contrast, stimulation with LPS, a ligand for TLR4, did not 
reactivate KSHV from latently infected B lymphocytes and did not induce significant changes in viral 
transcription. Additionally, we determined whether a physiological trigger of TLR7/8 could also 
reactivate KSHV. We infected PEL with a secondary pathogen, VSV, a known inducer of TLR7/8 
signaling, and found that VSV infection also induced KSHV reactivation from latency. Thus, our 
findings demonstrate a link between innate immune activation and viral reactivation from latency and 















We first screened latently infected PEL for TLR gene expression. BCBL-1 and BC-3 cells 
were harvested and expression of TLRs 1 through 10 were analyzed by qPCR with specific TLR 
primers. TLR profiling revealed that these cells express multiple TLRs, including TLR7 and TLR8 
(Figure 1A).  
To determine whether TLR activation could induce reactivation of KSHV, we stimulated 
BCBL-1 and BC-3 cells with individual cognate TLR ligands for 24 h, as well as a positive control, 
TPA (Figure 1B). Intracellular DNA viral load was determined by real-time PCR and normalized for 
input cell number using GAPDH copy number.  Fold activation for each sample was determined 
relative to the vehicle control using the ∆∆CT method. TLR2 stimulation with zymosan or TLR4 
stimulation with 10µg/ml LPS derived from Escherichia coli strain 0111:B4 showed no significant 
difference in lytic gene expression. Treatment of BCBL-1 cells with FSL-1 (TLR2/6 ligand) also had 
no significant effect on replication compared to vehicle control and neither did TLR9 stimulation with 
10µM CpG DNA. We observed a decrease in viral DNA copy number in response to 1µg/ml of 
recombinant flagellin (TLR5 ligand) or 10µg/ml polyI:C (TLR3 ligand). This was in contrast to 
stimulation with single-stranded RNA, a molecular pattern associated with viral infection that is 
recognized by TLR7 and TLR8 (27). Single-stranded poly-uridine (ssPoly-U) is a synthetic homolog 
of single-stranded RNA that specifically activates TLR8 (25, 26). Stimulation with 10µg/ml ssPoly-U 
resulted in a 4-fold increase in viral genome copy number compared to control (Figure 1B). 
Moreover, ssPoly-U reactivated KSHV to a greater extent than the positive control, TPA. In 
summary, ssPoly-U was the only TLR agonist that upregulated KSHV lytic gene expression, 
suggesting TLR8 activation reactivates KSHV from latency. 
Since KSHV does not replicate to high titers in PEL, quantification of DNA replication is not 
very sensitive.  We therefore tested TLR8-mediated reactivation of KSHV transcription in BCBL-1 
cells. BCBL-1 cells were treated with ssPoly-U for various timepoints. ORF57 and ORF49 mRNA 
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levels were subsequently analyzed by qPCR as a marker of viral reactivation. ssPoly-U treatment 
resulted in >10-fold reactivation compared to the vehicle control. In response to ssPoly-U, the levels 
of KSHV replication peaked at 48h and declined after 72h (Figure 1C).  For this experiment, we 
utilized a combination of both TPA and sodium butyrate (NaB) as a more potent positive control for 
KSHV reactivation, due to the variability in responses of individual PEL lines to TPA alone. This 
combination gives considerably higher reactivation levels than either agent alone.  To establish that 
TLR8-mediated reactivation was common to PEL in general, we screened additional PEL cells with 
ssPoly-U. BCBL-1, BC-3, BCP-1 or VG-1 cells were treated with ssPoly-U for 48hrs. This resulted 
in lytic reaction of KSHV in all samples (Figure 1D). This demonstrates that the activation of specific 










Figure 1:  TLR stimulation and KSHV reactivation.  A. TLR expression in PEL cells. Gene 
expression of TLRs 1-10 was determined in the PEL cell lines, BCBL-1 and BC-3, by quantitative 
RT-PCR (qRT-PCR) using primers specific to each human TLR gene. 18S gene expression was used 
as a loading control. B. KSHV reactivation in response to TLR agonists.  BCBL-1 cells were treated 
with 10µg/ml of the indicated TLR ligands and 20 ng/ml positive control (TPA) for 48h. DNA was 
isolated and KSHV replication was determined by qPCR for KSHV ORF49 or ORF57 gene 
expression compared to vehicle control. C. Time course of KSHV reactivation after TLR8 
stimulation. BCBL-1 cells were treated with vehicle control, ssPoly-U or a combination of TPA and 
Na-Butyrate. RNA was isolated at the indicated timepoints, and KSHV ORF49 and ORF57 gene 
expression was measured by qRT-PCR.  D. Single-stranded RNA reactivates KSHV from four 
different PEL. BCBL-1, BC-3, BCP-1 and VG-1 PEL cell lines were treated with vehicle control, 
50µg/ml ssPoly-U or a combination of TPA and Na-Butyrate for 48h. Fold reactivation was 
calculated using real-time PCR values of the TLR agonist treated samples versus the vehicle control 














We next queried the specificity of TLR7 and TLR8 for mediating KSHV lytic replication 
since both receptors recognize single-stranded RNA.   Both TLR7 and TLR8 reside within the 
endosome, have similar structures, and are often functionally redundant (20, 24, 26). We used several 
validated TLR7 and TLR8 ligands to test for KSHV reactivation in BCBL-1 cells.  CL-075 (3M-002) 
predominantly activates TLR8 and TLR7 to a lesser degree (25). Imiquimod has been shown to be 
specific for TLR7 (28).  We stimulated BCBL-1 cells with increasing concentrations of CL-075, 
Imiquimod, and CpG DNA (TLR9 ligand) and measured lytic gene transcription.  Increasing 
concentrations of CL-075 reactivated KSHV approximately 2.5- and 4.5-fold over mock (Figure 2A). 
Interestingly, the TLR7 ligand, Imiquimod, reactivated KSHV to similar levels as CL-075.  In 
contrast, increasing concentrations of TLR9 agonist (CpG DNA) had no effect. In summary, 
stimulation of TLR7 and TLR8 led to reactivation of latent KSHV.   We used the TLR4 agonist, LPS, 
as an additional negative control. We treated BCBL-1, BC-3, BCP-1 and VG-1 PEL cells with 10 and 
50µg/ml LPS derived from E. coli strain 0111:B4 (49). Increasing concentrations of LPS did not 
result in KSHV reactivation from latency (Figure 2B), whereas the positive control (TPA and NaB) 
did reactivate the virus.  Another TLR4 agonist, LPS from E. coli strain K12 (41), also failed to 























Figure 2:   TLR7/8, and not TLR4, reactivates latent KSHV. A. TLR7 and TLR8 ligands 
reactivate KSHV. BCBL-1 cells were treated with increasing concentrations of CL-075, Imiquimod, 
CpG DNA, or a combination of TPA and Na-butyrate for 48h. B. LPS does not activate KSHV 
replication. BCBL-1, VG-1, BCP-1 and BC-3 cells were treated with either LPS for 48h or a 
combination of TPA and Na-Butyrate. ORF57 transcription was measured by qRT-PCR using 






















TLRs 7 and 8 are known to signal through two pathways, NF-kB and IRF7, leading to the 
upregulation of pro-inflammatory cytokines and type I IFN, respectively. First, we looked at NF-kB 
activation following ssPoly-U stimulation by probing for IκB-α, an inhibitor of NF-κB nuclear 
translocation and transactivation. Upon activation of TLR7/8, IκB-α is ubiquitinated and targeted for 
proteasome-mediated degradation. Treatment of BCBL-1 cells with ssPoly-U for 5 hours induced 
IκB-α degradation (Figure 3A), indicating that the canonical NF-κB pathway was activated by 
TLR7/8 stimulation in PEL. Next, we tested whether the NF-κB promoter was activated in response 
to ssPoly-U in PEL. BCBL-1 cells were nucleofected with 200ng of NF-kB-luciferase plasmid. Cells 
were pooled after 48h, and either treated with ssPoly-U or vehicle control. Sixteen hours post-
treatment, cells were harvested and analyzed for luciferase activity. ssPoly-U treatment induced 
approximately 7-fold activation of the NF-kB reporter compared to vehicle treated cells (Figure 3B). 
Therefore, ssPoly-U potently activates NF-kB in BCBL-1 cells. ssPoly-U stimulation also induced the 
upregulation of IFN-α, IFN- β and IFN-γ, as well as NF-kB transcription in PEL (Figure 3C). 
Induction of NF-kB and IFN-α, β, γ  transcription serve as validated markers for the activation of 
TLR signaling in many different cell types (2-4). Moreover, activation of IFN-α/β induces IRFs 
(including IRF-7) in a positive feedback loop necessary for amplification of the initial innate immune 
response (46).  Therefore, we analyzed IRF-7 protein expression 24h after ssPoly-U stimulation of 
BCBL-1 cells and observed IRF-7 upregulation as expected (Figure 3D). To determine whether IRF-7 
was critical for TLR7/8 induced lytic replication downstream of TLR8, we transfected an IRF-7 
dominant negative (IRF7DN) construct (6) into BCBL-1 cells (Figure 3E, left). Forty-eight hours 
later, the cells were split into three samples and treated with equivalent amounts of either ssPoly-U, 
vehicle, or TPA. Twenty-four hours post-treatment, cells were harvested and lysates were analyzed 
for vIL-6 by Western blot. We found that IRF-7DN expression resulted in a marked reduction of 
KSHV lytic reactivation compared to mock treated cells (Figure 3E, right). Taken together, our data 
demonstrate that the TLR7/8 pathway is activated in response to ssPoly-U stimulation of PEL and 
imply that activation of this pathway can lead to KSHV reactivation from latency in B lymphocytes. 
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IRF7 is a critical component of this signaling pathway, whose activation by TLR7/8 is required for 



































Figure 3: Single-stranded RNA activates an innate immune response. A. Single-stranded RNA 
activates the canonical NF-kB pathway. IkB-α protein expression was determined by western blot 5 
hours post-treatment with ssPoly-U. B. Single-stranded RNA activates the NF-kB promoter in PEL.  
BCBL-1 cells were nucleofected with 200ng NF-kB promoter-luciferase plasmid and grown for 48h. 
Cells were then pooled and treated with ssPoly-U. Forty-eight hours post stimulation, cells were 
harvested and luciferase assays were performed. C. TLR7/8 stimulation activates type I IFN and 
NF-kB transcription. BC-3 and BCBL-1 cells were treated with 50µg/ml ssPoly-U for 48h. IFN-
α,b,g, NF-kB1, and NF-kB2 transcription levels were determined by qRT-PCR. All values were 
normalized to GAPDH as the endogenous control. D. IRF-7 expression is upregulated by single-
stranded RNA. Cells were harvested 24h post-treatment with ssPoly-U, and IRF-7 protein expression 
was analyzed by western blot. E. Inhibition of IRF-7 function blocks ssPoly-U induced KSHV 
reactivation. Flag-tagged IRF-7DN was analyzed by Western blot 48 hours after nucleofection of 
BCBL-1 cells (Left panel). pcDNA3-IRF-7DN or pcDNA3 vector control cells were treated with 
50µg/ml of ssPoly-U, equivalent amount of vehicle (mock sample), or 20ng/ml of TPA.  Twenty-four 
hours post-treatment, cells were analyzed for viral reactivation by performing a Western blot for vIL-












RTA/ORF50 is the key lytic switch protein of KSHV. It is necessary and sufficient to activate 
KSHV replication (14, 37). We therefore queried whether TLR7/8 signaling in PEL activated the 
KSHV RTA/ORF50 promoter. BCBL-1 cells were nucleofected with 5µg of ORF50 promoter-
luciferase reporter plasmid (9), and 48h post-transfection, cells were pooled and treated with ssPoly-U 
RNA or vehicle. After 16h, luciferase activity was quantified.  ssPoly-U treatment resulted in a 7-fold 
increase in luciferase activity compared to vehicle control (Figure 4A). Hence, ssPoly-U-induced 
TLR7/8 signaling can activate the RTA promoter.   
Next, we measured KSHV viral DNA in the ssPoly-U treated BCBL-1 cells (Figure 4B), and 
were able to detect a 4-fold increase in viral DNA levels. To corroborate these results, KSHV early 
lytic protein (ORF59) expression was analyzed by immunofluoresence assays (IFA) (11). KSHV 
ORF59 was detected in ssPolyU treated BCBL-1 cells as well as the positive control, but not in 
mock-treated cells (Figure 4C).  Similar results were obtained when we analyzed the expression of 
another KSHV lytic protein (vIL-6) in ssPoly-U treated cells by western blot analysis (Figure 4D). In 
summary, our data demonstrate that ssPoly-U stimulates the KSHV RTA promoter and induces 




























Figure 4:  Single-stranded poly-U RNA activates KSHV replication. A. ssPoly-U activates the 
KSHV RTA/ORF50 promoter. BCBL-1 cells were nucleofected with 5µg of RTAp-Luciferase 
reporter plasmid and 48h later cells were pooled and stimulated with ssPoly-U or vehicle control. 
Cells were harvested 48h post-treatment and relative luciferase activity compared to vehicle control 
was determined. B. KSHV viral load analysis. KSHV viral DNA was isolated 48h after treatment of 
BCBL-1 cells with ssPoly-U or vehicle control.  Quantitative PCR was performed with vIL-6 primers 
to determine viral DNA loads. C-D. ssPoly-U treatment induces the expression of KSHV lytic 
proteins. C. Immunofluorescence of KSHV ORF59 was performed 48h after ssPoly-U treatment. 
Nuclei were stained with DAPI. Pictures are depicted at 60X magnification. D. Western blot for 


















Although the above data suggested that KSHV lytic gene transcription and protein expression 
was activated by ssPoly-U treatment of PEL, it remained possible that lytic replication was 
incomplete. Therefore, we profiled genome-wide KSHV transcription using our KSHV qPCR array 
(9, 12, 17-19, 21, 45, 58).  We treated BCBL-1 and BC-3 cells with either ssPoly-U or TPA (positive 
control) for 48h and analyzed KSHV transcription.  Two independent cell lines, BCBL-1 and BC-3, 
showed upregulation of KSHV viral gene expression 48h after ssPoly-U treatment (Figure 5A). Their 
expression profile resembled that of the positive control, TPA. As a negative control, we treated 
BCBL-1 and BC-3 cells with 50µg/ml of LPS for 48h, but did not observe any KSHV reactivation 
(Figure 5A). LPS treated BCBL-1 cells displayed the transcription profile of the vehicle control-
treated cells.  
We also performed a time course experiment. BCBL-1 and BC-3 cells treated for 0h, 48h and 
72h with ssPoly-U or TPA displayed lytic replication at the 48h and 72h timepoints, with peak 
activation at 48h (Figure 5B).  These results indicate that complete KSHV lytic gene transcription 


















Figure 5: Whole genome profiling of KSHV after ssPoly-U treatment. A. ssPoly-U induces 
KSHV replication.  KSHV viral arrays were performed after treatment of BCBL-1 and BC-3 with 50 
µg/ml LPS, 50µg/ml ssPoly-U or a combination of TPA and Na-Butyrate.  Heat maps for each array 
are shown.  B. Time course of KSHV replication. Heat map of KSHV viral arrays after 0h, 48h and 
72h treatment with 50µg/ml ssPoly-U. Relative gene expression levels are represented by blue, white 
and red, which indicate no detectable, intermediate, or high KSHV gene expression, respectively.  C. 
ssPoly-U reactivation of PEL generates infectious KSHV virions. BCBL-1 and BC-3 cells were 
treated with 50µg/ml of ssPoly-U, an equivalent amount of vehicle, or 20ng/ml TPA. Forty-eight 
hours post-treatment, supernatants were harvested and used to infect Vero cells. Ninety-six hours 
post-infection of Vero cells, intracellular DNA was isolated and KSHV viral loads were quantified by 
qPCR using ORF57 primers. Values were normalized to GAPDH.  Fold increase in KSHV viral loads 

















To further verify infectious virus was produced by sspoly-U reactivation of PEL, we treated 
BCBL-1 and BC-3 cells for 48hr with 50µg/ml ssPoly-U.  Supernatants were subsequently harvested 
and used to infect uninfected Vero cells. 96hrs post-infection, viral DNA was isolated and KSHV 
viral loads were analyzed using qPCR with ORF57 primers. As shown in Figure 5C, treatment of 
BCBL-1 and BC-3 cells resulted in approximately 5- and 20-fold production of infectious KSHV 
virions, respectively. Of note, the endogenous levels of TLR8 in these two cell lines may correlate 
with differences in lytic replication between PEL cells. BCBL-1 cells have reduced levels of TLR8 
expression compared to BC-3 (Figure. 1A), which may explain observed differences in infectious 
virus produced upon ssPoly-U stimulation of PEL. 
 To demonstrate that TLR7/8 stimulation was necessary for ssPoly-U induced KSHV lytic 
replication, we used TLR7- and TLR8-specific shRNA vectors to create stable BCBL-1 cells 
containing knock-down of either TLR7 or TLR8.  A shRNA directed against luciferase was used as a 
control.  We achieved moderate knock-down of TLR7 and complete loss of TLR8 in our knock-down 
stable cells (Figure 6A).  
 BCBL-1 cells knocked-down for TLR7 or for TLR8 were used in ssPoly-U reactivation 
assays. Viral reactivation was measured by western blot analysis for the lytic protein, vIL-6. The 
control cell line, psiLuciferase-BCBL-1, showed considerable reactivation after treatment with 
ssPoly-U (Figure 6B). Treatment of psiTLR7-BCBL-1 with ssPoly-U resulted in slightly reduced 
vIL-6 expression, compared to the psiLuciferase-BCBL-1 treated cells, demonstrating a potential role 
for TLR7 in KSHV reactivation. However, ssPoly-U treatment of the psiTLR8-BCBL-1 cells 
displayed substantially reduced vIL-6 expression compared to the psiLuciferase-BCBL-1 treated 
cells. Importantly, all the knock-down cell lines remained similarly responsive to lytic reactivation by 
TPA, and showed considerable reactivation (Figure 6B).  In summary, while TLR7 may play a role in 
KSHV reactivation, TLR8 activation is more important for viral reactivation since the TLR8 knock-
down cells showed a significant reduction in ssPoly-U stimulated viral reactivation.  
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 To translate our results to a physiologically relevant setting, we used the single-stranded 
RNA virus, vesicular stomatitis virus (VSV), for infection of PEL.  VSV is endocytosed in a clathrin-
dependent manner (29, 33, 35, 52) and is known to activate TLR7/8 in mouse and human cells (22, 
38, 44, 59). BCBL-1 cells were infected with VSV at an MOI of 1, or treated with TPA as a positive 
control. KSHV vIL-6 protein expression was determined 24h and 48h post-infection. Infection with 
VSV resulted in KSHV reactivation at both time-points (Figure 6C). Similar results were seen with 
VSV infection at 0.1 MOI (data not shown). VSV-induced reactivation was also accompanied by 
increased NF-kB, IFN-α, β, and γ transcription (Figure 6D) and cell death was visually observed (data 




















Figure 6:  TLR7/8 stimulation mediates KSHV reactivation to single-stranded RNA and VSV 
infection. A. Knock-down of TLRs 7 and 8 in BCBL-1 cells. Western blot for TLR7 and TLR8 
protein expression in BCBL-1 cells stably transfected with the psiRNA-luciferase control, psiRNA-
TLR7, or psiRNA-TLR8 plasmids.  Tubulin is shown as a loading control   B. TLR7/8 mediate 
KSHV reactivation.  ssPoly-U treatment of psiRNA-luciferase, psiRNA-TLR7 and psiRNA-TLR8 
stable BCBL-1 cell lines.  Expression of the lytic protein, vIL6, was determined by western blot 24h 
after ssPoly-U treatment of each cell line. Tubulin is shown as a loading control.  C. VSV infection of 
PEL mediates KSHV reactivation.   BCBL-1 cells were infected with VSV at an MOI of 1. KSHV 
vIL-6 protein expression was determined by western blot 24h and 48h post-infection. D. VSV 
infection of PEL activates IFN gene transcription.  BCBL-1 cells were infected with VSV at an 
MOI of 1 and the cells were harvested 24h post-infection. The mRNA levels of IFN-α, β, γ, NF-kB1 

























 In summary, we report the first evidence for KSHV reactivation through TLR signaling. 
TLR7/8 mediated reactivation from latency offers a new paradigm for how KSHV may initiate lytic 
replication in vivo. Periodic reactivation of herpesviruses is important for the establishment of new 
latent reservoirs of virus, viral transmission, and persistence in the host. Since human herpesviruses 
establish life-long latency in their hosts, it is very plausible that a latently infected cell is exposed to 
infection by a secondary pathogen, be it a virus, bacterium or fungus.  We report that secondary viral 
infection that is dependent on endosomal entry and stimulation of TLR7/8 signaling can lead to 
reactivation of latent KSHV from B lymphocytes. It is well-established that VSV activates TLR7/8.  
Although VSV is a rhabdovirus and a natural pathogen of livestock, human infections have been 
documented (30, 54), and VSV can infect human B lymphocytes (47).  Other RNA viruses that 
activate TLR7/8, such as dengue virus, also infect B lymphocytes (36). Of note, it was previously 
reported that infection of PEL with VSV-pseudotyped HIV particles reactivated KSHV (55), although 
the exact mechanism was not deduced.  Since HIV RNA is known to activate TLR7 and TLR8 (16, 
27), the observed outcome in this earlier study may be attributable to HIV RNA-induced activation of 
TLR7/8 in PEL.  
In immunosuppressed KSHV-positive individuals, KSHV reactivation rates may be increased 
by secondary infections that trigger TLR7/8 activation. Since lytic replication of KSHV is linked to 
an increased risk of KSHV-associated cancers (15, 42, 51), one can speculate that KSHV-positive 
individuals exposed to TLR7/8-activating pathogens are at a higher risk of developing KSHV-
associated malignancies. Endogenous RNAs from necrotic cells also activates TLR7/8 (50). Hence, it 
is equally plausible that KSHV reactivation is triggered by endosomal trafficking of endogenous 
RNA from necrotic cells.   
Lastly, our data have implications for oncolytic therapy of viral cancers.  There is a growing 
interest in using VSV oncolysis to treat tumors (6). Our data suggests that VSV infection of KSHV-
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infected lymphomas results in oncolysis, but also reactivates KSHV.  This may be detrimental to 
KSHV-positive cancer patients since VSV oncolysis would inadvertently aid viral reactivation and 
dissemination. Thus, for some viral cancers it may be advisable to use VSV oncolytic treatment in 
combination with viral replication inhibitors, such as ganciclovir, to prevent reactivation and spread 
of the virus to naïve cells in the host. 
 Defining the physiological stimuli of reactivation from latency is a fundamental question in 
herpesvirus biology. We report the first evidence of innate immune receptors mediating KSHV 
reactivation.  Moreover, TLR7/8 signaling mediated by secondary infection of KSHV-infected B 
lymphocytes not only induces KSHV reactivation and lytic replication, but also allows the virus to 
propagate itself and escape a cell that is fated to die. This ensures KSHV survival and persistence for 
















Materials and Methods 
Cell culture 
 PEL cells were maintained in RPMI 1640 medium (Cellgro) containing 10% fetal bovine 
serum (FBS), 1% penicillin-streptomycin (PS) and 0.05 M beta-mercaptoethanol.  Vera, HeLa and 
BHK cells were maintained in 10% FBS and 1% PS. Cells were maintained at 37C in 5% carbon 
dioxide. 
TLR expression 
 Toll-like receptor screening of PEL cell lines was carried out by isolating RNA, generating 
cDNA as described below and analyzing gene expression by quantitative real-time PCR using TLR 
and 18S specific primers (SA Biosciences) according to manufacturer’s instructions. qPCR products 
were resolved on 1% agarose gel. 
TLR stimulations and real-time PCR 
 1x10
5
 cells/ml of the indicated PEL cells were resuspended in 500µL of 2% FBS/RPMI and 
added to 48-well plates. TLR agonists (Invivogen) FSL-1 (TLR2/6), zymogen (TLR2), poly I:C 
(TLR3), lipopolysaccharide (TLR4), recombinant flagellin (TLR5), imiquimod (TLR7), gardiquimod 
(TLRs 7/8), CL-097 (TLR7), single-stranded poly U (TLR 8) and CpG DNA (TLR9) were 
reconstituted in water according to manufacturers recommendations and TLR stimulations performed 
at the indicated concentrations. Positive control stimulations were performed with 20ng/ml TPA 
(Sigma) and 0.1mM Na-butyrate (Sigma) in DMSO. For intracellular viral load assays, DNA was 
isolated using DNeasy kit according to manufacturer’s instructions (Qiagen). For KSHV 
transcription, cells were harvested and RNA isolated using RNeasy Plus RNA isolation kit (Qiagen) 
followed by treatment with 1 unit of RQ1 DNase (Promega). cDNA was reverse transcribed from a 
minimum of 100ng of RNA using MMLV reverse transcriptase (Invitrogen) and random hexamer 
primers (Invitrogen). Fold gene expression compared to mock treated samples was determined by 
quantitative-polymerase chain reaction (qPCR) using Sybr GREEN PCR master mix (Applied 
Biosystems) and primers for KSHV ORF49 (Forward: ACAAAATGGGAGAGGCACCA; Reverse: 
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GCGGCCCTGGAATCAGA) and ORF57 (Forward: TGGACATTATGAAGGGCATCCTA; 
Reverse: CGGGTTCGGACAATTGCT). All activation increases were normalized to glyceraldehyde-
3-phosphate-dehydrogenous (GAPDH) (Forward: GAAGGTGAAGGTCGGAGT; Reverse: 
GAAGATGGTGATGGGATTTC) expression. IFN and NF-kB gene transcription was determined 
using primers IFN-α (Forward: GTGAGGAAATACTTCCAAAGAATCAC; 
Reverse:TCTCATGATTTCTGCTCTGACAA), IFN-β (Forward: 
CAGCAATTTTCAGTGTCAGAAGC; Reverse: TCATCCTGTCCTTGAGGCAGT), NF-kB1 
(Forward: GGTGAAGGGAGACCTGGCTT; Reverse: GTGCCTCAGCAATTTCTGGC), NF-kB2 
(Forward: TTCTGAAGGCTGGTGCTGAC; Reverse: AGTGAGGTCAAGAGGCGTGT), IFN-γ 
(Forward: TCAGCTCTGCATCGTTTTGG; Reverse: GTTCCATTATCCGCTACATCTGAA).  
The qPCR reactions were run on an ABI 7000 or ABI 7300 machine. Relative fold calculations were 
determined by the ∆∆CT method (36). 
Promoter reporter assays 
 5x10
6
 BCBL-1 cells were nucleofected (Amaxa) using T-01 program and B-cell specific 
nucleofection kit (Amaxa) with either 200ng of pGL3-ELAM-luc NF-κB promoter luciferase reporter 
plasmid (Addgene) or 5µg of KSHV ORF50 promoter luciferase reporter plasmid. 48hrs post-
nucleofection, cells were pooled and stimulated with TLR agonists as described above. 16hrs post-
TLR stimulation, total cell protein was harvested and luciferase expression quantified as previously 
described (18). Fold relative luciferase units were calculated over mock treated samples.  
IRF-7 Dominant Negative (IRF-7DN) Assays 
 1x10
6 
BCBL-1 cells were nucleofected as described above using 2µg of Flag-tagged 
pcDNA3-IRF-7 dominant negative plasmid (a kind gift from Drs. Shunbin Ning and Joseph Pagano) 
or pcDNA3 vector control. 48hrs post-nucleofection, cells were split into three samples and each 
sample was stimulated with either ssPoly-U, vehicle, or TPA for 24 hours. Expression of IRF-7DN 
was verified by Western blot with an anti-Flag antibody.  
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KSHV viral arrays  
 A high-throughput, real-time quantitative reverse transcription KSHV gene array was 
developed by Fakhari and Dittmer to quantify KSHV gene expression (40).  BCBL-1 cells were 
treated with TLR agonists for 48hrs unless otherwise noted. RNA was isolated and cDNA generated 
as described previously (40). Hierarchical clustering was performed using ArrayMinerTM software 
(Optimal Design, Brussels, Belgium) as previously described (35). 
KSHV Infection Assay 
 BCBL-1 or BC-3 cells were treated with either ssPoly-U, vehicle or TPA as described above 
for 48 hours.  Supernatants were harvested and added to confluent monolayers of uninfected Vero 
cells in a 12-well dish. Polybrene (4mg/ml) was added to each well and the plate was spinoculated at 
2500 rpm for 1.5 hours at 30°C as previously described (18). Ninety-six hours post-infection, 
intracellular KSHV viral loads were determined by real-time PCR as described above.  
Western Blot procedure 
 Cell lysates were prepared in RIPA lysis buffer containing 150 mM NaCl, 1% NP40, 50mM 
Tris pH 8, 0.5% Na-deoxycholate, 0.1% SDS, 100mM sodium vanadate, 0.5M NaF, 1mg/ml 
Leupeptin, 1 tablet per ml of complete protease inhibitor solution (Roche), 100mM PMSF and 1M 
DTT. Proteins were resolved on either 8% or 10% SDS-PAGE gels for TLR or vIL-6 expression, 
respectively, and transferred to nitrocellulose membranes. Membranes were incubated in either 5% 
non-fat milk (NFDM) or bovine-serum albumin (BSA) for 1hr at RT, followed by 3X washes in 1X 
TBS, 0.1% Tween buffer. TLR7 and TLR8 (Abcam) antibodies were incubated overnight at 4C in 5% 
NFDM. vIL-6 (ABI) and b-tubulin (Sigma) antibodies were incubated at 1:2000 overnight in 5% 
NFDM. IRF-7 (Cell Signaling) antibody was incubated at 1:50 overnight in 5% BSA. The blots were 
probed with either anti-mouse (Jackson Laboratories) or anti-rabbit (Cell Signaling) horseradish-
peroxidase conjugated secondary antibodies at 1:2500 and 1:2000 in 5% NFDM or BSA. IκB-α (Cell 
Signaling) was used at 1:1000 in 5% BSA overnight at 4°C. Flag-tagged IRF-7DN was detected with 




 BCBL-1 cells were stimulated with 50ug/ml ss-PolyU or TPA (20ng/ml) for 24hrs followed 
by fixation onto microscope slides with 1% paraformaldehyde for 30 minutes. Next, fixed cells were 
washed with 1% bovine serum albumin (BSA), 1X PBS and permeabilized with a 0.1% triton-X 100, 
1X PBS solution for 20 minutes at room temperature. Slides were washed 2X and then KSHV ORF59 
antibody was added at a dilution of 1:50 in 1% BSA, 1X PBS overnight at 4°C in a humidified 
chamber. Next, slides were washed 2X in PBS and FITC-conjugated anti-mouse (Sigma) was added 
at 1:50 in 1%BSA, 1X PBS for 1hr at RT. Slides were washed 2X and stained with DAPI (4,6-
diamidino-2-phenylindole) nuclear stain (0.5 µg/ml in water) for 5 minutes at RT, followed by 1X 
wash. Coverslips were affixed with Vectorshield (Vector Laboratories). ORF59 and DAPI staining 
was visualized using Nikon Microphoto FXA Upright fluorescence microscope.  
Stable knock-down of TLR7 and TLR8 in BCBL-1 cells 
 1x10
6
 BCBL-1 cells were transfected by either nucleofection (Amaxa) or Hyperfect reagent 
(Qiagen) with short-hairpin plasmids psiRNA-Luciferase (Invivogen), psiRNA-TLR7 (Invivogen) or 
psiRNA-TLR8 (Invivogen). 48hrs post nucleofection, cells were placed in 100µg/ml Zeocin. BCBL-1 
cells stably expressing psiRNA-Luciferase, psiRNA-TLR-7 or psiRNA-TLR8, were verified by GFP 
and TLR7 or TLR8 protein expression as described above. Viral reactivation assays were performed 
as described above. 
Vesicular stomatitis virus infections 
 Vesicular stomatitis virus (Orsay strain; a kind gift from Dr. Doug Lyles) was grown on 
HeLa cells for 72hrs. Supernatants were aspirated and centrifuged at 2500 RPM for 5 minutes to clear 
cellular debris. Viral titers were determined by infecting baby hamster kidney (BHK) cells at 0.1 MOI 
for 72hrs followed by plaque assay. 1x10
5
 BCBL-1 were infected with 0.1 and 1.0 MOI for 24 and 
48hrs in 2% RPMI, in a 48-well dish at 37°C. Cell lysates were subjected to western blot analysis for 
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The nucleotide-binding and oligomerization, leucine-rich repeat (NLR) family of proteins 
sense microbial infections and activate the inflammasome, a multi-protein complex that promotes 
microbial clearance.  Kaposi’s sarcoma-associated herpesvirus (KSHV) is linked to several human 
malignancies. We report that KSHV Orf63 is a viral homolog of human NLRP1. Orf63 blocked 
NLRP1-dependent innate immune responses, including caspase-1 activation and processing of 
interleukin (IL)-1β and IL-18. KSHV Orf63 interacted with NLRP1, NLRP3, and NOD2. Inhibition 
of Orf63 expression resulted in increased expression of IL-1β during the KSHV lifecycle. 
Furthermore, inhibition of NLRP1 was necessary for efficient reactivation and generation of progeny 
virus. The viral homolog subverts the function of cellular NLRs, which suggests that modulation of 





Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) is the etiological agent of several 
human cancers including Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD) (4, 5). The ability of KSHV to evade host innate immunity is essential 
for productive infection, latency and life-long persistence (6). 
Several families of pattern recognition receptors (PRRs) have been described: Toll-like 
receptors (TLRs), nucleotide-binding and oligomerization, leucine-rich repeat (NLR) proteins, 
retinoic acid inducible gene (RIG)-I-like receptors (RLRs) and C-type lectin receptors (CLRs) (16, 
21). Upon recognition of pathogen-associated molecular patterns (PAMPS), PRRs signal immune cell 
activation. TLRs play an important role in the lifecycle of KSHV (10, 29), but whether NLRs also do 
is unknown.  Over twenty NLR family members have been identified in humans, and polymorphisms 
in several NLRs are linked to various autoinflammatory diseases (2, 14, 17, 20, 25). Activation of a 
subset of NLRs by PAMPs causes the formation of large multimeric complexes termed 
inflammasomes, which are composed of oligomers of a specific NLR, procaspase-1 and apoptotic-
associated speck-like (ASC) adaptor protein (19). Inflammasome formation results in the proteolytic 
processing of proinflammatory cytokines IL-1β and IL-18 by active caspase-1.  Excessive IL-1β and 
IL-18 production in response to pathogen infection is associated with pyroptosis, an inflammatory 












KSHV Orf63 is an uncharacterized tegument protein. Basic Local Alignment Search Tool for 
proteins (BLASTP) of NLRP1 and KSHV Orf63 revealed that these proteins are homologous (E 
value=0.0002) and that Orf63 showed significant similarity to the LRR domain of NLRP1 (fig. S1A). 
A ClustalW2 alignment of the two proteins also showed homology of the nucleotide-binding domain 
(NBD) of NLRP1 (fig. S1A) and full-length NLRP1 (fig. S1B) with KSHV Orf63. However, KSHV 
Orf63 does not contain the effector caspase activation and recruitment domain (CARD) or pyrin 
domain (PYD) of NLRP1, which are required for its activation, suggesting that Orf63 may function as 
an inhibitor of NLRP1.  
To investigate whether Orf63 inhibits NLRP1 activity, THP-1 cells stably expressing Orf63 
and control cells were primed with lipopolysaccharide (LPS) to upregulate IL-1β transcription, 
followed by stimulation of NLRP1 with the bacteria cell wall constituent, muramyldipeptide (MDP). 
We found that Orf63 expression significantly inhibited MDP-induced IL-1β and IL-18 production 
compared to control cells (Fig. 1A-D and fig. S2A). Furthermore no changes in the inflammasome-
independent cytokine, tumor necrosis factor (TNF)-α, were observed, confirming the specificity of 
Orf63 inhibition of the NLRP1 inflammasome (fig. S2B).   
Inflammasome activation leads to production of proinflammatory cytokines and eventual cell 
death. In cells expressing Orf63, NLRP1-dependent cell death (as measured by lactate dehydrogenase 
(LDH) activity) was significantly inhibited compared to vector alone (Fig. 1E), demonstrating that 
Orf63 protects cells from NLRP1-dependent cell death.   
To further examine the role of Orf63 in blocking NLRP1, we transfected 293T cells with 
Orf63 and the NLRP1 inflammasome components ASC, procaspase-1 and pro-IL-1β (9). 
Reconstitution of the NLRP1 inflammasome resulted in an increase in IL-1β secretion, which was 
inhibited by expression of Orf63 in a dose-dependent fashion (Fig. 1F and G). In contrast, another 
KSHV viral protein, replication and transcription activator (RTA) was unable to inhibit IL-1β 
secretion (fig. S2C).  We also investigated the ability of Orf63 to inhibit caspase-1 enzymatic activity. 
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Transfection of procaspase-1 and NLRP1 into 293T cells resulted in increased caspase-1 specific 
activity that was inhibited by co-expression of Orf63 (Fig. 1H). Furthermore, NLRP1-induced 




















Figure. 1. Orf63 is a viral homolog and inhibitor of NLRP1. (A-D) Stable Orf63 expression in 
THP-1 cells is detected by immunoblot (top panel in A). THP-1-Control and THP-1-Orf63 cells were 
either treated with vehicle control or primed with 5ng/ml LPS for 1 hour, followed by stimulation 
with 10µg/ml MDP for 6 hours. Supernatants were harvested and analyzed for IL-1β by enzyme 
linked immunosorbent assay (ELISA) and values were normalized to extracellular lactate 
dehydrogenase (LDH) released (A) or analyzed for pro-IL-1β and cleaved IL-1β by immunoblot (B). 
Supernatants were also analyzed for IL-18 by ELISA and normalized to extracellular LDH (C) and by 
immunoblot (D). (E) THP-1-Control or THP-1-Orf63 cells were treated as described above and 
extracellular LDH was calculated relative to positive control.  (F) Procaspase-1, pro-IL-1β, ASC 
(together denoted as CIA) and NLRP1 expression plasmids were transfected into 293T cells with 
Orf63 or vector control. Cell extracts and supernatants were harvested 24 hours later and subjected to 
an IL-1β ELISA and immunoblot for cleaved IL-1β (G) 293T cells were transfected with the 
indicated expression constructs followed by immunoblot for IL-1β expression. (H) NLRP1 and 
procaspase-1 were transfected into 293T cells with Orf63 or vector control for 24 hours. Caspase-1 
enzymatic activity was determined by incubating lysates with caspase-1 substrate, WEHD-7-amino-4-
trifluoromethyl coumarin (AFC). Fluorescence emission was measured every 15 minutes for 2 hours. 
(I) Caspase-1 was immunoprecipitated from 293T cells transfected with the indicated expression 
plasmids followed by immunoblot.  ** indicates statistical significance P ≤ 0.05 by two-tailed 










Next, we investigated whether Orf63 could interact with NLRP1. Orf63 co-
immunoprecipitated with NLRP1, and vice versa, in 293T cells co-transfected with plasmids to 
express these proteins (Fig. 2A and B). Endogenous NLRP1 was also shown to interact with Orf63 
when Orf63 was expressed in THP-1 cells (fig. S2D). Thus, Orf63 is capable of interacting with 
NLRP1 and/or in a complex with components of the NLRP1 inflammasome. To investigate the latter 
scenario, we tested the ability of Orf63 to interact with ASC or caspase-1. We found that Orf63 did 
not interact with either ASC or caspase-1 in the absence of NLRP1 (fig. S3).  Next, Orf63 was 
immunoprecipitated from a mixture of purified Orf63 made in bacteria and purified NLRP1 made in 
insect cells, and we found that NLRP1 protein co-immunoprecipitated with Orf63, suggesting that 
Orf63 directly interacts with NLRP1 in the absence of other proteins (Fig. 2C).  
To identify the structural elements of NLRP1 that were required for interaction with Orf63, 
we tested several domain mutants of NLRP1 (3). KSHV Orf63 interacted with the NBD, LRR and 
FIIND (function to find) domains of NLRP1, whereas no interaction was observed with the PYD and 
CARD effector domains of NLRP1 (Fig. 2D and fig. S4A-D). The LRR domain of NLRP1 is thought 
to negatively regulate its activation by folding back onto the NBD domains (9, 27). Interaction of 
Orf63 with NLRP1 suggests that Orf63 may be functioning similarly to the NLRP1 LRR to block 
activity.  Sequence alignments indicated that Orf63 most closely aligned with the LRR and NBD 
domains of NLRP1 (fig. S1A). Hence, we created mutants of Orf63; Orf63-N, which contains most of 
the region similar to NBD but lacks the region that aligns with the LRR, and Orf63∆N, which 
contains the entire LRR and only a part of the NBD (fig. S5A), and tested the ability of these mutants 
to bind NLRP1 by co-immunoprecipitation assays. Either domain was sufficient for interacting with 
NLRP1 (Fig. 2E) similar to previous reports on  NLR proteins (8, 11) .  Furthermore, in NLRP1 
inflammasome reconstitution assays, both Orf63 mutants were capable of inhibiting NLRP1 activity 















Figure. 2. Orf63 interacts with NLRP1. (A) 293T cells were transfected with expression plasmids 
for NLRP1, Orf63 or both plasmids and 48 hours later, NLRP1 was immunoprecipitated followed by 
immunoblotting for Orf63. (B) A reverse immunoprecipitation was performed. 293T cells were 
transfected with expression plasmids for NLRP1, Orf63 or both plasmids and 48 hours later, Orf63 
was immunoprecipitated followed by immunoblotting for NLRP1. (C) Co-immunoprecipitation of 
purified Orf63 and NLRP1-GST proteins followed by immunoblotting for Orf63-FLAG and GST-
NLRP1. (D) 293T cells were transfected with Orf63 and full-length or mutant NLRP1 expression 
plasmids followed by immunoprecipitation of Orf63 and immunoblotting for NLRP1. (E) 293T cells 
were transfected with Orf63-N and Orf63∆N mutants and full-length NLRP1 expression plasmids for 
48 hours. Immunoprecipitations were performed for NLRP1 followed by immunoblots for Orf63-N 
and Orf63∆N mutants. Asterisk indicates non-specific band in input lanes. Data are representative of 

















The NLRP1 inflammasome is comprised of multiple proteins complexed with NLRP1, 
caspase-1 and ASC (19). Our data demonstrate that Orf63 can inhibit NLRP1 function and can also 
interact with NLRP1. To determine the mechanism of NLRP1 inhibition, we tested the ability of 
Orf63 to bind NLRP1 and to inhibit the formation of the NLRP1 inflammasome.  The presence of 
Orf63 inhibited the interaction of NLRP1 with procaspase-1, but not its interaction with ASC (Fig. 
3A and fig. S6A and B).  NLRP1 oligomerization has been shown to be required for activation (9). 
We confirmed that NLRP1 self-associates and found that Orf63 blocked this self-association (Fig. 
3B). Gel fractionation analysis under native conditions revealed that the presence of Orf63 caused 
more NLRP1 to fractionate in the lower molecular weight fractions, where Orf63 is also expressed 
(fig. S6C). This provides further support that Orf63 inhibits NLRP1 oligomerization. Taken together, 
our findings indicate that Orf63 hinders inflammasome formation by both preventing NLRP1 
oligomerization and inhibiting the association of NLRP1 with procaspase-1.  
NLRP1 can also interact with NOD2 and this interaction enhances its activity in terms of 
inflammasome function (13). Reciprocal immunoprecipitations revealed that Orf63 interacts with 
NOD2 (Fig. 3C). Similar to NLRP1, the interaction of Orf63 with NOD2 required the NBD domain 
(fig. S7A). In contrast, Orf63 did not interact with NOD1 (fig. S7B).   
 NLRP1 activation and subsequent IL-1β and IL-18 secretion is detrimental to viral infection. 
We hypothesized that inhibition of Orf63 would result in increased proinflammatory cytokine 
production during KSHV infection. KSHV has been shown to infect human monocytes (29), therefore 
we isolated primary human monocytes from blood from healthy donors (fig. S8A and B) and infected 
them with KSHV in the presence and absence of siRNAs against Orf63 (Fig. 3D). We detected 
increased IL-1β expression and decreased viral gene expression in KSHV-infected monocytes 
transfected with siRNAs targeting Orf63 compared to non-targeting control (Fig. 3E and F, 
respectively).  
We next determined the effect of Orf63 during viral reactivation. KSHV-293T cells 
containing  endogenous NLRP1 were transfected with a plasmid encoding RTA to induce KSHV 
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reactivation and lytic gene expression (26). Knockdown of Orf63 resulted in a statistically significant 
increase in IL-1β expression compared to non-targeting control (fig. S9A and B).  Reconstitution of 
cells with the NLRP1 inflammasome inhibited expression of KSHV reactivation as measured by 
expression of the vIL-6 lytic protein (fig. S9C); however, when only the LRR domain of NLRP1, 
which is an inhibitor of NLR activity (9, 24, 27), was co-transfected with the inflammasome 
components, vIL-6 expression was restored (fig. S9C).   
Similarly, when NLRP1 expression was knocked-down in KSHV-infected latent BCBL-1 
primary effusion lymphoma (PEL) cells (fig. S10A), we detected an increase in viral genomes and 
infectious virus, which was enhanced after induction of lytic replication (fig. S10B and C).  To 
confirm that Orf63 is necessary for KSHV lytic gene expression, we inhibited Orf63 expression in 
BCBL-1 PEL cells using Orf63 siRNA. Orf63 siRNA transfected PEL showed a significant loss of 
Orf63 expression (Fig. 3G).  Further, Orf63 knockdown resulted in the loss of lytic gene expression 
as measured by loss of Orf49 and Orf57 viral lytic transcript expression (Fig. 3G). After knockdown 
of Orf63 in reactivated PEL, supernatant was transferred to naïve Vero cells and viral infectivity on 
Vero cells was quantitated by real-time PCR. We found that Orf63 knockdown resulted in a block of 
infectious virus produced during PEL reactivation (Fig. 3H). Taken together, our data show that 
Orf63 can block NLRP1 activation and the production of IL-1β. This function of Orf63 appears to be 
critical for viral gene expression and viral genome replication during KSHV primary infection as well 


























Figure. 3. Orf63 inhibits NLRP1 inflammasome formation and is necessary for IL-1β inhibition 
during viral infection. (A) Indicated expression plasmids were transfected into 293T cells. NLRP1 
was immunoprecipitated 48 hours later and procaspase-1 interactions with NLRP1 were determined 
by immunoblot. (B) 293T cells were transfected with indicated expression plasmids for 48 hours. 
NLRP1-myc was immunoprecipitated with anti-myc-antibody and interactions with NLRP1-V5 
detected by immunoblot. (C) 293T cells were transfected with indicated expression plasmids 
followed by immunoprecipitation of either Orf63 or NOD2 48 hours later. Interaction of Orf63 with 
NOD2 was detected by immunoblot (D) KSHV-infected primary human monocytes were transfected 
with siRNAs against Orf63 or non-targeting controls. 48 hours later, Orf63 and GAPDH transcription 
was analyzed by PCR. (E) Control and Orf63 siRNA monocytes were analyzed for IL-1β expression 
by ELISA 48 hours after transfection with Orf63 siRNA or non-targeting control siRNA. (F) 
Transcription of lytic viral genes, Orf49, Orf50 and Orf57, in KSHV-infected monocytes was 
analyzed by qPCR 48 hours after knock-down of Orf63. (G) BCBL-1 PEL cells were nucleofected 
with siRNAs against Orf63 or a non-targeting control. 24 hours later, the cells were treated with 
25ng/ml TPA. 96 hours post-TPA treatment, Orf49, Orf57 and Orf63 transcription was analyzed by 
qPCR. (H) BCBL-1 PEL cells were treated as in panel G, and 96 hours later, supernatants were used 
to infect naïve Vero cells. 72 hours later, KSHV viral load in the infected Vero cells was determined 
by qPCR for Orf49. ** indicates statistical significance P ≤ 0.05 by two-tailed student’s t-test. Data 










BLASTP alignments revealed homology of Orf63 to the NBD and LRR domains of NLRP1, 
which are conserved motifs among the NLR family members. To investigate whether Orf63 could 
also inhibit the activation of other NLR family members, we stimulated THP-1-Orf63 or control 
THP-1 cells with several NLRP3 agonists (25). Orf63 inhibited IL-1β and IL-18 cleavage and 
production after treatment with the NLRP3 agonists, ATP and Alum (Fig. 4A-D, fig. S11 and fig. 
S12A-D).    Orf63 also protected cells from NLRP3-dependent cell death in response to these agonists 
as measured by a LDH release assay (Fig. 4E and fig. S12E). Orf63 co-immunoprecipitated with 
NLRP3 when both proteins were exogenously expressed in 293T cells (Fig. 4F). Furthermore, 
35
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Figure. 4. Orf63 inhibits the NLRP3 inflammasome. (A-D) THP-1-control or THP-1-Orf63 cells 
were mock treated or primed with 5ng/ml LPS for 1 hour followed by stimulation with 2.5mM ATP 
for 6 hours. Supernatants were harvested and analyzed by ELISA for IL-1β and normalized to 
extracellular LDH (A) or for pro-IL-1β and cleaved IL-1β by immunoblot (B). ATP-stimulated cells 
were also examined for IL-18 expression by ELISA and values were normalized to extracellular LDH 
(C) and pro-IL-18 and cleaved IL-18 by immunoblot (D). (E) THP-1-control or THP-1-Orf63 cells 
were treated with ATP as described above and subjected to an LDH release assay. (F) 293T cells 
were transfected with NLRP3 and Orf63 expression plasmids for 48 hours. NLRP3 was 
immunoprecipitated followed by immunoblotting for Orf63. (G) GST and GST-Orf63 was purified 
and subjected to SDS-PAGE and Coomassie staining. (H) GST or GST-Orf63 protein was incubated 
with glutathione beads and 35S-methionine-labeled NLRP1, NLRP3 or luciferase protein as 
previously described (7). Complexes were washed several times and subjected to SDS-PAGE.  The 
gel was dried and the bound radiolabeled proteins were detected by a phosphorimager.  The first three 
lanes represent 20% of the input of each of the three labeled proteins added to the GST and GST-
Orf63 binding reactions. ** indicates statistical significance P ≤ 0.05 by two-tailed student’s t-test. 













KSHV exists in diverse cell types including monocytes, B cells, epithelial, and endothelial 
cells (1, 22, 23). NLRP1 is ubiquitously expressed compared to NLRP3, which is more restricted in 
its expression (12, 18). Herpesviruses establish life-long latency and must encode proteins that 
function in the context of all types of cellular events including adverse circumstances. Given KSHV’s 
broad tropism, it seems advantageous for KSHV to encode an inhibitor of the inflammasome.  
The NLR nomenclature requires that in order to be classified as a NLR, the protein must 
contain a NBD and a LRR domain, which are two domains that are evolutionarily conserved in all 
NLRs (28). Poxviruses encode a pyrin-only containing protein named M13L that inhibits IL-1β and 
IL-18 secretion (15) through a different mechanism since M13L lacks both a NBD and a LRR 
domain.  KSHV Orf63 does show homology to both the NBD and LRR domains of NLRs and is a 
homolog of NLRP1.  We also found that another herpesvirus encodes a viral homolog of NLRP1 
(Fig. S13). This suggests that the targeting of NLR proteins might play a very important role in the 
herpesvirus lifecycle.  
KSHV encodes a viral homolog of cellular NLRP1 without the CARD and PYD effector 
domains of its cellular counterpart.  Although Orf63 did not demonstrate significant similarity to 
NLRP3, it blocked NLRP3 activity, suggesting that Orf63 is capable of broad inhibition of NLR 
inflammasome responses. Thus, during the course of evolution with its human host, KSHV has 





Supplemental Figures  
 
Supplemental Figure 1A: Alignment of KSHV Orf63 with NLRP1 
Amino acid alignments were performed using BLASTP and ClustalW2 bioinformatics programs with 
Orf63 (NCBI accession# YP_001129420.1) and human NLRP1 (NCBI accession # NP_127499). The 














Supplemental Figure 1B: Alignment 
of KSHV Orf63 with NLRP1 
Amino acid alignment of the full-length 
KSHV Orf63 and human NLRP1 
proteins performed using the ClustalW2 

































Supplemental Figure 2: KSHV Orf63 but not KSHV RTA inhibits NLRP1-mediated IL-1β 
secretion. 
(A) 0.5 x106 THP-1 vector control cells or Orf63-expressing cells were primed with 5ng/ml LPS for 
1 hour followed by stimulation with 1µg/ml, 10µg/ml and 50µg/ml MDP. Supernatants were 
harvested 6 hours later followed by an ELISA for extracellular IL-1β secretion. The IL-1β values 
were normalized to LDH (B) THP1 cells were treated as described above with 10 µg/ml MDP and 
TNF-α expression was analyzed by ELISA. (C) NLRP1, procaspase-1, ASC and pro-IL-1β 
expression plasmids were transfected into 293T cells with Orf63, RTA or vector control. Supernatants 
were harvested 24h later and subjected to ELISA for extracellular IL-1β expression and expression of 
each component was depicted by immunoblot. (D) Immunoprecipitation of Orf63 from THP-1 cells 
followed by detection of endogenous NLRP1 by immunoblot using anti-NLRP1 antibody. Asterisk 
indicates non-specific band. ** indicates statistical significance P ≤ 0.05 by two-tailed student's t-test. 
















Supplemental Figure 3: Orf63 does not interact with NLRP1 inflammasome components ASC 
and caspase-1. (A-B) 293T cells were transfected with expression plasmids for Orf63 and either ASC 
(A) or caspase-1 (B) and 48h later, immunoprecipitation of Orf63 (A) or caspase-1 (B) was 










Supplemental Figure 4: The NBD of NLRP1 is required, but not sufficient for interactions with 
Orf63. (A) Summary of NLRP1 mutants and Orf63's interactions with NLRP1. (B-D) Expression 
plasmids encoding PYD and CARD (B) or ∆PYD, PYD+NBD, ∆LRR, LRR and FIIND (C) or 
∆CARD (D) mutants of NLRP1 were cotransfected into 293T cells with Orf63. Forty-eight hours 













Supplemental Figure 5: Orf63-N and Orf63∆N mutants are capable of inhibiting NLRP1 
activity. (A) Panel depicting Orf63 mutants. Orf63-N, which contains amino acids 1-200, and 
Orf63∆N, which contains amino acids 201-928. (B) NLRP1 inflammasome was reconstituted by 
transfecting 293T cells with NLRP1, ASC, procaspase-1 and pro-IL-1β expression plasmids and 
wild-type Orf63, Orf63-N or Orf63∆N mutants. Twenty four hours post-transfection, supernatants 
were analyzed for IL-1β by ELISA. ** indicates statistical significance P ≤ 0.05 by two-tailed 
student's t-test. Data are representative of at least three experimental replicates, with standard 



























Supplemental Figure 6: Orf63 inhibits the interaction of procaspase-1 with NLRP1 and NLRP1 
oligomerization. (A-B) Expression plasmids encoding NLRP1, ASC (A) and procaspse-1 (B) with 
either vector control or Orf63 were transfected into 293T cells. 48h later, NLRP1 was 
immunoprecipitated and immunoblots for each protein were performed. (C) 293T cells expressing 
NLRP1 or co-expressing NLRP1and Orf63 were lysed under native conditions and subject to gel 
filtration analysis. Fractions were isolated and subjected to immunoblotting to detect the presence of 























Supplemental Figure 7: NOD2 NBD is required for interactions with Orf63, and Orf63 does not 
interact with NOD1. (A) Full-length NOD2 or NOD2 mutants were transfected into 293T cells. 48h 
later, Orf63 was immunoprecipitated and NOD2 interactions detected by immunoblot. * indicates 
nonspecific band. (B) 293T cells were transfected with Orf63 and NOD1 expression plasmids for 
48h. Orf63 was immunoprecipitated and the immunoprecipitates were subjected to western blot 








Supplemental Figure 8: Purity of primary human monocytes purified from healthy donors. (A-
B) Human monocytes were isolated from peripheral blood mononuclear cells (PBMC) and analyzed 
by flow cytometry. Forward and side scatter (A) and CD14 expression (B) plots are shown to 
demonstrate purity. Percentage of cells that are CD14+ is determined by calculating the number of 
















Supplemental Figure 9: Orf63 inhibits IL-1β expression during KSHV reactivation. 
(A) KSHV-293T cells were transfected with RTA or vector control expression plasmids and either 
control siRNA (siControl) or Orf63-targeting siRNA (siOrf63) as well as plasmids encoding 
procaspase-1, ASC and pro-IL-1β. RNA was harvested 24 hours later and cDNA was synthesized. 
Orf63 and GAPDH transcription levels were determined by PCR amplification and agarose gel 
electrophoresis. ~ indicates non-specific band. (B) KSHV-293Ts were transfected as described above 
and supernatants harvested 48 hours later. Extracellular IL-1β was determined by ELISA. (C) KSHV-
293T cells were transfected with procaspase-1, pro- IL-1β, ASC, NLRP1 and either vector control or 
RTA expression plasmids. 72 hours post-transfection, reactivation and vIL-6 expression (indicator of 
lytic protein expression) was analyzed by immunoblot. ** indicates statistical significance P ≤ 0.05 
by two-tailed student's t-test. Data are representative of at least three experimental replicates, with 





























Supplemental Figure 10: NLRP1 inhibits KSHV reactivation from latency and production of 
infectious progeny virus. (A) BCBL-1-shRNA-control and BCBL-1-shRNA-NLRP1 stable 
knockdown cell lines were analyzed for NLRP1 expression by immunoblot. (B) BCBL-1or BCBL-1-
shRNA-NLRP1 stable knockdown PEL cells were mock treated or treated with 25ng/ml TPA 
followed by analysis of viral genomes 96 hours post-treatment by qPCR. (C) BCBL-1-shRNA-
control or BCBL-1-shRNA-NLRP1 PEL cells were treated as in panel B, and 96 hours later, 
supernatants were used to infect naïve Vero cells. 72 hours later, KSHV viral load in the infected 
Vero cells was determined by qPCR. ** indicates statistical significance P ≤ 0.05 by two-tailed 
student's t-test. Data are representative of at least three experimental replicates, with standard 




















Supplemental Figure 11: Orf63 inhibits NLRP3 in a dose-dependent manner. 
A dose-response graph for ATP treatment in control versus Orf63-expressing THP-1 
cells. THP-1 control cells or Orf63-expressing cells were stimulated with LPS as 
described followed by stimulation with 0.25mM, 0.5mM or 25mM ATP. Supernatants 
were harvest 6 hours later and IL-1β secretion was analyzed by ELISA. The IL-1β 
values were normalized to LDH. ** indicates statistical significance P ≤ 0.05 by twotailed 
student's t-test. Data are representative of at least three experimental replicates, with standard 












Supplemental Figure 12: Orf63 inhibits the NLRP3 inflammasome. (A-D) THP-1-control or 
THP-1-Orf63 cells were mock treated or primed with 5ng/ml LPS for 1 hour followed by stimulation 
with 130µg/ml Alum for 6 hours. Supernatants were harvested and analyzed by ELISA for IL-1β (A) 
or for pro- IL-1β and cleaved IL-1β by immunoblot (B). Alum-stimulated cells were also examined 
for IL-18 expression by ELISA (C) and pro-IL-18 and cleaved IL-18 by immunoblot (D). For both 
IL-1β and IL-18 ELISAs, values were normalized to LDH. (E) THP-1-control or THP-1-Orf63 cells 
were treated with ATP as described above and subjected to an LDH release assay. ** indicates 
statistical significance P ≤ 0.05 by two-tailed student's t-test. Data are representative of a minimum of 
three experimental replicates.  Data are representative of at least three experimental replicates, with 



















Supplemental Figure 13: Rhesus monkey rhadinovirus (RRV) Orf63 demonstrates homology to 
NLRP1. Amino acid alignments were performed using BLASTP and ClustalW2 (depicted) 
bioinformatics programs with RRV Orf63 (NCBI accession# YP_001129420.1) and human NLRP1 



















Materials and Methods 
Bioinformatics: NCBI BLASTP for NLRP1 and Orf63 was performed using the amino acid 
sequence of NLRP1 (NCBI accession # NP_127499) and the amino acid sequence of KSHV Orf63 
(NCBI accession# YP_001129420.1). The ClustalW2 program was used to align the full-length 
sequence of NLRP1 isoform 1 (NCBI accession # NP_127497), NLRP1 isoform 3 (NCBI accession # 
NP_127499.1), NOD2 (NCBI accession # Q9HC29), KSHV Orf63 (NCBI accession # YP 
001129420.1), and RRV Orf63 (NCBI accession # AAF60049). 
Reagents: Total RNA was harvested from THP-1 cells with TriZol and, cDNA synthesis was 
performed using Superscript III reverse transcriptase. PCR reactions were performed using Pfx DNA 
polymerase with primers designed to the open reading frames of procaspase-1, pro-IL-1beta, NOD1, 
NOD2, and NLRP3. The amplicons were cloned into pCDNA3.1D to make V5 tagged pcDNA3-
procaspase1-V5, pcDNA3-pro-IL-1β-V5, and pcDNA3-NOD2-V5 plasmids. Epitope tags were 
interchanged using annealed oligonucleotides for FLAG (pcDNA3-ASC-FLAG, pcDNA3-NOD1-
FLAG) or Myc (pcDNA3-NLRP3-myc) using standard procedures. Sequence fidelity was verified by 
DNA sequencing. Expression was verified by immunoblot analysis to epitope tags of transfected 
plasmids. pUNO-NLRP1 was purchased from Invivogen. pcDNA3-NLRP1-V5 was generated by 
amplifying isoform 1 of NLRP1 by PCR and subcloning into pcDNA3. KSHV Orf63 was amplified 
by PCR using primers adding BamH1 and EcoRV restriction sites with a FLAG epitope tag at the c-
terminus. Amplified Orf63 was cloned into pcDNA3 vector to generate pcDNA3-Orf63-FLAG. The 
same procedure was used to generate pcDNA3-Orf63-V5. Orf63-N-FLAG and Orf63∆N-FLAG were 
generated by cloning fragments encoding amino acids 1-200 (Orf63-N) and 201-928 (Orf63∆N). To 
generate GST-tagged Orf63, Orf63 was subcloned from pcDNA3-Orf63-FLAG using BamH1 and 
Not1 restriction sites and cloned into pGex5p-1 vector. pcDNA-NLRP1- myc, accompanying myc-
tagged mutants and GST-tagged NLRP1 were previously described (15). 
Cell lines: BCBL-1, THP-1-Orf63 and THP-1-Control cells were maintained in RPMI medium 1640 
(Cellgro) containing 10% FBS and 1% penicillin-streptomycin (PS). 293T and lentivirus producer 
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293FT cells were maintained in DMEM medium (Cellgro) with 10% FBS and PS. KSHV-293T were 
maintained as 293T with 1mg/ml Puromycin. Cells were maintained at 37 °C in 5% carbon dioxide. 
BCBL-1-shRNA-NLRP1 and BCBL-1- shRNA-non-targeting cell lines were generated by 
nucleofecting BCBL-1 cells with shRNA-NLRP1 or shRNA-non-targeting (Santa Cruz) control 
plasmids. Nucleofected cells were selected for expression of shRNA plasmids by the addition of 
1.0ug/ml puromycin. Knock-down of NLRP1 was confirmed by immunoblotting for NLRP1 (Cell 
Signaling). 
NLRP1 Inflammasome Reconstitution Assays: 0.2 x 106 HEK293T cells were seeded in 24-well 
plates in cell culture media lacking antibiotics. 24 hours later, cells were transfected with 200ng 
pUNO-NLRP1 (Invitrogen), 5ng ASC-FLAG, 5ng pro-caspase-1-V5 and either 5ng human pro-IL-
1β-V5 or 20ng mouse pro-IL-1β (14) using lipofectamine2000 (Invitrogen). 24 hours later, cell 
lysates and supernatants were harvested and analyzed for IL-1β secretion and expression by ELISA 
(BD) or immunoblot, respectively. Secreted IL-1β levels were generally normalized by using a LDH 
release assay (see below) to normalize for cell death. For immunoblotting, cleaved IL-1β (Cell 
signaling) or murine IL-1β (R&D Systems) antibodies were used to detect human cleaved- or mouse 
pro- and cleaved-IL-1β expression, respectively. Immunoblots of extracellular IL-1β were performed 
after precipitation with trichloracetic acid. 
Orf63-Lentivirus Production and Infection: Orf63-FLAG was subcloned into pLenti7.3 lentivirus 
expression system (Invitrogen) according to manufacturer’s instructions. Briefly, Orf63-FLAG was 
PCR amplified to include a 5’-terminus KOZAK sequence and subcloned into pENTR Gateway 
vector to yield pENTR-Orf63-FLAG (Note: stop codon not mutated to enable FLAG epitope 
detection). Next, pLenti7.3- Orf63-FLAG was generated by performing LR recombination reaction 
between pENTROrf63- FLAG and pLenti7.3 expression vector. A clone containing pLenti7.3 that did 
not recombine was isolated as a negative control. Orf63 expression was confirmed by transfecting 
into 293T cells and performing anti-FLAG immunoblots. To generate lentivirus, pLenti7.3-Orf63-
FLAG or control pLenti7.3 were transfected into 293FT cells (Invitrogen) with ViraPower Packaging 
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Mix. Virus was harvested 72 hours later. Transduction of THP-1 cells was performed by 
centrifugation of 5 x 106 cells with 1 ml virus, 8ug/ml polybrene for 3 hours at 3000 rpm at room 
temperature (RT). Twenty-four hours later, the transduction was repeated to enhance infection. The 
transduced cells were sorted for GFP expression by flow cytometry and Orf63 expressing clones 
isolated by limiting dilution. Expression of FLAG-tagged Orf63 in THP-1-Orf63 cells was confirmed 
by immunoblot. 
THP-1 Stimulations: 1 x 106 pLenti7.3 or pLenti7.3-Orf63 cells were plated in 12-well plates in 
500ul RPMI containing 2% FBS and PS. Cells were either mock treated or primed with 5ng/ml 
lipopolysaccharide (Sigma) for 1 hour followed by treatment with 10µg/ml muramyldipeptide 
(Sigma), 2.5mM adenosine triphosphate (ATP), or 130µg/ml Alum (Thermo Scientific) for 6 hours at 
37 °C. Supernatants were harvested and clarified by centrifugation at 1500rpm at RT and cytokine 
analysis was performed as described below. 
Immunoblot and Co-immunoprecipitation Assays: Cell lysates were prepared in 0.1% NP-40 lysis 
buffer containing protease inhibitor cocktail (Roche). Proteins were resolved on either 10% or 12.5% 
SDS-PAGE gels and transferred to PVDF membranes by wet transfer. Membranes were blocked for 1 
hour in 5% non-fat dry milk (NFDM) containing 0.1% TBS-Tween 20 and washed 3X in 0.1% TBS-
Tween 20 at room temperature. Monoclonal, horse-radish peroxidase (HRP) conjugated antibodies 
(Sigma) to M2-FLAG, C-myc, and V5 epitopes were used to detect expression of epitope tagged 
proteins. IL-1β and cleaved IL-1β antibodies (Cell signaling) were used at 1:1000 in 5% bovine 
serum albumin overnight followed by anti-rabbit-HRP secondary antibody (Cell Signaling) to detect 
the 34kDa and 17kDa forms of IL-1β. Detection of cleaved IL-1β in supernatants was performed by 
concentrating supernatants using Millipore YP-10 centrifugal filter devices or trichloroacetic acid 
precipitation followed by immunoblot. For co-immunoprecipitation studies, antibodies against the 
FLAG, V5 or c-myc epitopes were used to precipitate proteins in the presence of 20µl protein A/G 
beads (Santa Cruz) overnight at 4ºC. Protein complexes were washed four times in either lysis or 
RIPA buffer, incubated at 95ºC for 5 minutes and resolved by immunoblot. To detect Orf63’s 
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interaction with endogenous NLRP1, Orf63 was immunoprecipitated from THP-1 cells 24 hours 
following nucleofection (Amaxa) using anti-V5 monoclonal antibody (Sigma) as described above. 
Endogenous NLRP1 was detected by immunoblotting using human anti-NLRP1 antibody (Cell 
Signaling). For direct immunoprecipitation, Orf63 was expressed in BL21 Escherichia coli cells by 
induction with 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 2 hours at 37ºC. GST-Orf63 
was purified with GSTsepharose (Amersham). GST-sepharose-Orf63 was incubated with precision 
protease overnight at 4ºC. Cleaved Orf63 was further purified by incubation with anti-FLAG-M2 
antibody for 1 hour at 4ºC followed by incubation with protein A/G beads for 3 hours. Next, beads 
were washed 5 times with lysis buffer to remove unbound Orf63 and resuspended in 1ml lysis buffer 
and purified NLRP1. Mouse IgG (Santa Cruz) control reactions were also prepared. Orf63 and 
NLRP1 were incubated overnight at 4ºC, washed 4 times with lysis buffer and NLRP1 interactions 
were detected by immunoblotting for NLRP1. 
In-vitro transcription/translation: [35S]-methionine (Perkin-Elmer) labeled NLRP1, NLRP3 and 
control luciferase proteins were prepared using TnT T7 Quick Coupled Transcription/Translation 
System (Promega) according to manufacturer’s instructions. pcDNA3-NLRP1 and pcDNA3-NLRP3 
plasmids were used for the transcription/translation reaction. 
GST binding Assay: Expression and purification of GST fusion proteins were performed as 
previously described (29) and equal amounts of GST and GST-Orf63 were bound to glutathione 
beads (29). Equivalent amounts (1x105 cpm) of 35S-methionine labeled NLRP1, NLRP3 and 
luciferase proteins were incubated with the GST and GSTOrf63 bound protein in NETN+ buffer plus 
protease inhibitors for an hour at 4ºC. NETN+ buffer comprised of 20 mM Tris (pH 7.5), 100 mM 
NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM DTT. The bound complexes were washed five times (5 
minute washes) in NETN+ buffer. The samples were subjected to SDS-PAGE. The gel was fixed, 
dried and exposed to a phosphoimager. 
Gel Filtration Assay: HEK293T cells were plated in 15cm dishes in antibiotic-free media. 24 hours 
later, cells were transfected with NLRP1-myc or NLRP1-myc and Orf63-flag expression plasmids 
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with lipofectamine2000 as described. 24 hours posttransfection, cells were washed with ice-cold 1X 
PBS followed by lysis in hypotonic buffer (20mM HEPES-KOH pH7.5, 10mM KCL, 1.5mM MgCl2, 
1mM EDTA, 1mM EGTA and Roche Protease Inhibitor Cocktail) and shearing with 27-gauge 
needle. Soluble lysates were run over a Superose 6 gel filtration column (GE Lifesciences) using a 
Bio-Rad Duoflow chromatography system. Column elution fractions were analyzed for comigration 
of NLRP1 and Orf63 by immunoblot for myc and FLAG, respectively.  
Caspase-1 Fluorescence Assay: Caspase-1 fluorescence assay (R&D systems) was performed 
according to manufacturer’s instructions: Briefly, 293T cells were transfected as described above. 
Twenty-four hours later, cells were washed in ice-cold 1X PBS, and whole cell extracts prepared. 
50µL of extract was added to 50µL of 2X reaction buffer containing DTT, followed by 5µL of 
WEHD- 7-amino-4-trifluoromethyl coumarin (AFC) substrate. Caspase-1 activity was measured 
every 15 minutes over 2 hours using a fluorescence plate reader at 505nm. 
ELISA: Supernatants were analyzed for cytokine expression using IL-1β, TNF-α (BD Biosciences) 
and IL-18 (R&D Systems) ELISAs according to the manufacturer’s instructions. IL-1β secretion was 
normalized by the LDH release assay. 
Lactate-Dehydrogenase Release Assay: LDH release assays (Promega) were performed according 
to the manufacturer’s instructions. LDH release data was used to normalize IL-1β secretion in 293T 
inflammasome reconstitution and THP-1 stimulation assays to account for cell death. 
Reactivation Assays: KSHV-293T cells were seeded at 0.5 x 106 cells per well in a 6- well plate. 
Cells were transfected 24 hours later with plasmids encoding procaspase-1, ASC, pro-IL-1β, RTA or 
vector control, along with either 50nM Orf63 ON-TARGET (Dharmacon) siRNA (Sense: 
AGACAAAGCUGUUGAUGGAUU, Antisense: UCCAUCAACAGCUUUGUCUUU) or control 
non-targeting siRNA (Dharmacon).Cells and supernatants were harvested forty eight hours later. 
Supernatants were subjected to IL-1β ELISA while total RNA was isolated from the cell pellets. In 
order to confirm knockdown of Orf63, cDNA was generated and used as a template for PCR with 
Orf63 primers (Sense: CCCACTACGCGGATCAGATA, Antisense: 
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GCTCTTGCATAATGCCTCTA). GAPDH primers were used for loading control. PCR products 
were resolved on a 1% agarose gel. NLRP1 inhibition of reactivation was performed by coexpressing 
NLRP1 inflammasome components as described above with RTA or vector control. vIL-6 expression 
was analyzed by immunoblot 72 hours postreactivation.         
Inhibition of KSHV reactivation in BCBL-1. 1 x 106 BCBL-1-shRNA-NLRP1 or BCBL-1-
shRNA-control cells were either mock treated or treated with 25ng/ml TPA (Sigma). Viral genomes 
were analyzed by qPCR using primers specific for Orf49 as previously described 96 hours post-
reactivation (6). 
Analysis of KSHV transcription: 2.5 x 106 BCBL-1 cells were nucleofected with siRNAs against 
Orf63 or non-targeting control. 24 hours later, cells were either mock stimulated or treated with 
25ng/ml TPA for 96 hours. Orf49 and Orf57 viral gene transcription was analyzed as previously 
described (6). 
Human Primary Monocyte Infections: KSHV was grown and purified as previously described (7). 
Primary human monocytes were isolated from peripheral blood mononuclear cells by negative 
selection using the monocyte isolation kit II from Milltenyi Biotec. Purification of monocytes was 
verified by flow cytometry for CD14 (Miltenyi Biotec) and average purities were greater than 98%. 
Immediately following purification, 1.5 x 107 monocytes were infected with KSHV by centrifugation 
at 2000 rpm at 30ºC for 1 hour. KSHV-infected monocytes were cultured in 20% FBS. 48 hours post-
infection, media was changed to antibiotic free media. 72 hours post-infection, productive infection 
was confirmed by fluorescent microscopy. Next, siRNAs against Orf63 or non-targeting control were 
transfected by Lipofectamine RNAimax (Invitrogen) according to manufacturer’s instruction. 120 
hours post-infection, supernatants were analyzed for IL-1β expression by ELISA and knockdown of 
Orf63 tested by PCR. qPCR for Orf49, Orf50 and Orf57 transcription was assessed as previously 
described (6). 
Statistical Analysis: Data were analyzed for statistical significance by two-tailed student’s t-test in 
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Kaposi's sarcoma (KS)-associated herpesvirus is the etiologic agent of Kaposi's sarcoma, 
primary effusion lymphoma and multicentric Castleman's disease. KSHV can infect a number of cell 
types including B cells, endothelial cells, epithelial cells and monocytes.  We report the establishment 
of a monocytic cell line that is latently infected with KSHV (KSHV-THP-1).  To study the host 
response to KSHV infection, we compared gene expression in KSHV-THP-1 cells to uninfected 
THP-1 cells.  We found that several genes involved in the host immune response were selectively 
downregulated in the KSHV-infected monocytic cell line. These included tumor necrosis factor 
(TNF), interleukin-1β, CXCL10 and CCL4.  Interestingly, CD86 and CD83, CD80 and CD1a 
costimulatory molecules were also downregulated in KSHV-THP-1 cells.   
We also profiled eighty-four viral genes in the KSHV-THP-1 cells and found that KSHV 
predominantly exhibited a latent gene profile. Latency associated genes such as LANA, v-Cyclin and 
v-FLIP were expressed in the KSHV-infected monocytes. Taken together, our findings suggest 
KSHV specifically infects antigen presenting cells to actively suppress global cellular gene 




Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 
(HHV8), is a member of the gammaherpesvirus subfamily.  KSHV is the etiological agent of 
Kaposi’s sarcoma (KS) (8), primary effusion lymphoma (PEL) and multicentric Castleman’s disease 
(MCD) (1, 8, 35).  KS is a highly inflammatory and angiogenic vascular tumor defined by 
characteristic spindle cells, which are believed to originate from endothelial cells.  PEL and MCD are 
both B lymphoproliferative diseases. 
 Like other herpesviruses, KSHV can establish latent infection in its host. A number of PEL 
cell lines have been established where most of the cells are latently infected, with only a small 
population of cells undergoing spontaneous lytic reactivation (26, 37).  During latency, a limited 
number of viral proteins are expressed, including the latency-associated nuclear antigen (LANA), 
vFLIP, vCyclin, kaposin and K15 (34, 36).  Maintenance of the viral genome is absolutely dependent 
on the LANA protein, which tethers the latent viral episome to the host cell chromosome, ensuring 
that the viral genome is replicated with the host genome and is not diluted out of the expanding 
population of latently infected cells (10, 13).  The LANA protein has been shown to be expressed in 
latently infected B cells and endothelial cells, as well as in the tumors associated with these cell types 
(3, 10, 13). 
It has previously been shown that KSHV can successfully infect human monocytes and 
macrophages in vitro and in vivo (4, 5, 7, 22).  Rappociolo et al. demonstrated that KSHV uses the 
receptor DC-SIGN to enter monocyte-derived macrophages and dendritic cells (29, 31). However, in 
THP-1 acute monocyte-like leukemia cells, KSHV primary infection did not require DC-SIGN(18). 
Instead, infection was dependent on α3β1, αvβ3, αvβ5 and α5β1 integrins and proceeded by endosomal 
entry, which activated FAK, Src, PI3K, NF-kB and ERK1/2 signaling.    Co-infection of monocytes with 
KSHV and HIV greatly increased the replication of HIV in the presence of KSHV (7).  Monocytes 
present in KS lesions have been shown to support viral replication (6).  Additionally, KSHV has been 
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found to infect CD34+ stem cell precursors in vitro, suggesting stem cells may be infected and 
subsequently differentiate into B cells and monoctyes to replenish depleted pools of infected, 
differentiated cells (42).  
Immunological detection of KSHV infection by T cells requires T cell receptor (TCR) 
cognate interactions with antigen presenting cells’ major histocompatibility complex (MHC) surface 
molecules displaying KSHV peptide. On inactivated T cells, CD28 is expressed at low levels, and 
upon TCR: MHC contact, as well as APC surface receptor CD40 ligating CD40 ligand (CD40L), 
CD28 expression is highly upregulated. Concomitantly, costimulatory molecules CD80 and CD86 on 
the APC are highly upregulated, which interact with CD28 to increase the immune response. Despite 
the existence of KSHV-specific T cells and immune control in healthy individuals, latent KSHV is 
unable to be eliminated from the host (39, 40). It is known that lytic proteins K3 and K5 of KSHV 
actively downregulate CD80 and MHC class I (MHCI) surface expression, however, the suppression 
of adaptive immune molecules during latency also contributes to evasion of the host response (20). 
Cells involved in immunity that are tropic for KSHV may enable suppression of KSHV-targeted 
immune responses.  
Given the fact that KSHV infects monocytes in vivo, we made a latently infected monocytic 
cell line using the acute monocytic leukemia cell line, THP-1, to characterize cellular and viral gene 
expression profiles in latently infected monocytes.  Importantly, although we have previously shown 
that KSHV can infect primary human monocytes (41), we could not establish a long-term latent 
culture in these cells because of the primary nature of the monocytes. However, a monocytic cell line 
such as THP-1 enables establishing a latent cell line that harbors KSHV and that can be passaged 
indefinitely. 
The latently infected monocytes expressed LANA with characteristic speckle staining. Viral 
genes that were expressed in the latently infected monocytes included LANA, vCyclin, vIRF-1 and 
vIRF-3. We found that KSHV infection of THP-1 cells downregulated a number of genes involved in 
the immune response to pathogen infection as well as costimulatory molecules that are necessary for 
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adaptive immune responses. Infection of monocytes and suppression of cellular mechanisms of 
immune recognition during latency suggests KSHV specifically targets APCs to prohibit activation of 


























Materials and Methods 
Production of recombinant rKSHV.219 virus  
  Vero cells containing latent rKSHV.219 (KSHV-Vero) and a recombinant baculovirus KSHV 
Orf50 (BacK50) were kindly provided by Dr. Jeffrey Vieira (38).  rKSHV.219 expresses green 
fluorescent protein (GFP) and also contains a puromycin resistance gene as a selectable marker. 
Insect SF9 cells were grown in Grace’s insect media (Gibco) supplied with 10% fetal bovine serum 
(FBS) at 28°C in a 5% CO2 incubator. SF9 cells were infected with baculovirus expressing KSHV 
Orf50 (Bac50) for three days, after which time the baculovirus-containing supernatant was clarified 
by centrifugation (3500 rpm for 10 min). KSHV-Vero cells were then infected with Bac50 and treated 
with 1mM sodium butyrate for three days. Supernatant was harvested and cells were removed by 
centrifugation (3500 rpm for 10 min).  Supernatants were subsequently passed through a 0.45µm 
filter. 
Establishment of the KSHV-THP-1 cell line. 
THP-1 cells were cultured in RPMI with 10% FBS and were maintained at 37°C in a 5% CO2 
environment. rKSHV.219 produced from KSHV-Vero cells was used to infect THP-1 cells.  We first 
made an infection cocktail containing complete RPMI media and rKSHV.219 supernatants (volume 
ratio 1:2) with 4 µg/ml polybrene. THP-1 cells were centrifuged at 1500 rpm for 5 min, and then 
2×10
6
 THP-1 cells were resuspended in 3 ml infection cocktail, and added to one well of a 6-well 
plate. The cells in the 6-well plate were spun for 90 min at 30°C at 2500 rpm, then the supernatants 
were removed and the cells were resuspended in 3 ml complete RPMI media. The cells were 
incubated in a 37°C incubator for 72 hours, and then were selected with complete RPMI media 




THP-1 or KSHV-THP-1 cells were air-dried onto microscope slides and then fixed with 0.4% 
formaldehyde for 30 minutes. Cells were washed 2X with PBS for 5 minutes, permeabilized with 
PBS, 0.1% Triton X-100 for 20 minutes and washed 2X with PBS, 1% BSA for 5 minutes. Incubation 
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with primary antibody anti-HHV8-ORF73 (Advanced Biotechnologies) (1:500) was performed for 
16hrs at 4C. Cells were washed with PBS, 1% BSA 2X for 5 minutes and incubated with anti-Rat-
TRITC conjugated secondary antibody (Sigma), 1:500 for 1hr at room temperature. Cells were 
washed 2X with PBS, 1% BSA for 5 minutes, and then stained with 4', 6-diamidino-2-phenylindole 
(DAPI) for 2 minutes. Next, cells were washed with PBS, 1% BSA for 5 minutes followed by ddH20 
for 5 minutes. Microscope slides were mounted using Vectorshield (Vector Laboratories) mounting 
medium and visualized using Nikon Microphot FXA Upright fluorescence microscope.  
Viral Microarrays 
 1 x 10
6 
THP-1 or KSHV-1 THP-1 cells were harvested and total RNA isolated by RNease kit 
(Qiagen) according to the manufacturer’s instructions and then DNase treated using DNA Free RNA 
Kit (Zymo Research). cDNA is synthesized using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) as directed by manufacturer. 
  Viral gene profiling was performed as previously described (11, 12).  Cycle threshold values 
(CT) were determined by automated analysis. The threshold was set to five times the standard 
deviation (SD) of the non-template control (NTC). For each PCR run, dissociation curves were 
analyzed to verify that identical primer-specific, single reaction products were generated in each run. 
Hierarchical clustering was performed using SPSS v11.0 (SPSS science, Chicago, IL) (11, 12). 
Samples were normalized to GAPDH levels, centered by median of gene, and ordered by hierarchical 
clustering using ArrayMiner™ (Optimal Design Inc., Brussels, Belgium) software with standard 
correlation metrics.  
Quantitative reverse-transcription PCR (QPCR) 
 Individual genes that showed significant differences in the cellular microarrays were 
confirmed by QPCR analysis. 1 µg DNase-treated total cellular RNAs from THP-1 or KSHV-THP-1 
cells were reverse transcribed into cDNA using a Reverse Transcription System from Promega. The 
real-time PCR was done with ABI 7300 Real Time PCR Machine using SYBR Green PCR Master 
Mix (Applied Biosystems). Primer sets for all amplicons are shown in Table 1. PCR was carried out 
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with 1 cycle of 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 
1 min. All fold activations were normalized by GAPDH expression in the samples, and all of the PCR 
products were used to run 1% agarose gels. 
Flow Cytometry 
 For assessment of expression of cell surface receptors, THP-1 and KSHV-THP-1 monocytes 
were suspended at 1 X 10
7
 cells/ml in staining buffer (1X PBS, 2%BSA) and labeled with 20 ul of 
either mouse APC conjugated anti-Human CD86 (BD Pharmingen), mouse APC conjugated anti-
human CD83 (BD Pharmingen) or isotype control APC conjugated IgG1 kappa (BD Pharmingen) 
antibodies for 30 min at 4ºC protected from light. Cells were then thoroughly washed 2X with 
staining buffer by centrifugation at 1500 rpm at 4ºC. Next, labeled cells were fixed using 1% 
formaldehyde for 30 min at 4ºC, followed by washing with staining buffer. Samples were 
resuspended in 250ul of staining buffer and analyzed by BD FACs Calibur (BD Biosciences) flow 
cytometer with data analysis using Summit version 4.3 (Dako). Data was acquired for a minimum of 
25000 total events.  
Western Blotting 
 THP-1 or KSHV-THP-1 cells were washed in ice-cold 1X PBS and lysed by 3X dry 
ice/ethanol fractionations in RIPA lysis buffer. Cell lysates were centrifuged at 13,000 rpm, 4ºC for 
10 minutes. Protein quantifications were performed using Bradford protein quantification assay. 25ug 
of whole-cell lysate was resolved by SDS-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membranes by wet-transfer 30V, overnight at 4ºC. Transfers are verified by Ponceau S 
staining, followed by blocking in 5% non-fat dry milk (NFDM), 1X PBS, 0.2% Tween-20. Following 
3X washes in 1X PBS, 0.2% Tween-20 for 10 minutes at room temperature (RT), membranes were 
incubated with primary antibody overnight at 4ºC. Rabbit monoclonal anti-human CD86 (Novus 
Biologicals) or Rabbit monoclonal anti-human CD80 (Novus Biologicals) were diluted in 5% NFDM 
at 1:5000 and 1:10000, respectively. Following incubations, membranes were washed 3X and 
incubated with anti-rabbit IgG (Cell Signaling) in 5% NFDM at 1:2000 for 1 h at RT. Following 3X 
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washes, membranes were developed using Amersham ECL Plus Western Blotting Detection Reagents 
(GE Healthcare).  
Cytokine Expression Analysis 
 1 x 10
6
 THP-1 or KSHV-THP-1 cells were plated in 12-well plates containing complete 
medium. After incubation at 37ºC for 24hrs, supernatants were harvested and cleared of cell debris by 
centrifugation at 1250 rpm for 10 minutes. Supernatants were analyzed for cytokine expression of 
using Millipore Luminex multianalyte technology according to the manufacturer’s instructions and in 
collaboration with the University of North Carolina Center for Gastrointestinal Biology and Disease 





















Establishment of KSHV-infected THP-1 monocytes and KSHV viral profiling. 
KSHV can successfully infect human monocytes and macrophages in vitro and in vivo (4, 5, 7, 
22). THP-1 is a human acute monocytic leukemia cell line and has been extensively used in the 
literature as a human monocytic model cell line (2).  We infected THP-1 cells with rKSHV.219 
expressing green fluorescent protein (GFP) driven by the CMV promoter, red fluorescent protein 
(RFP) under a lytic viral promoter, and puromycin resistance gene (38).  Seventy-two hours post-
infection, cells were added to puromycin containing selection media to maintain KSHV infection and 
to achieve a hundred percent KSHV-infected monocyte cell line as monitored by GFP expression 
(Figure. 1).  Importantly, even though a majority of cells were latent for KSHV infection, there 
appeared to be some cells that were undergoing lytic reactivation as measured by red fluorescent 
protein expression driven by the lytic PAN promoter (38). This is analogous to the situation in PEL. 














Figure 1: KSHV infection in THP1 cells. Fluorescence microscopy of GFP expression in KSHV-
THP-1 cells (top panel) compared to uninfected THP-1 control cells (bottom panel). Images obtained 













In order to determine the profile of KSHV viral genes expressed in the THP-1 monocytic cell 
line, real time quantitative PCR (QPCR) was performed in KSHV-THP-1 cells and uninfected THP-1 
cells. Quantitative real-time PCR primers pairs were designed for each KSHV ORF as previously 
described (11).  Equal amounts of total poly(A) mRNA from THP-1 and KSHV-THP-1 cells were 
used as starting material. Figure 2A plots cycle threshold (Ct) values for each KSHV gene and the 
relative log fold gene expression of KSHV-THP-1 compared to uninfected THP-1 for each KSHV-
specific primer pair. LANA and several other classic latent genes including vCyclin and vIRF-3 are 
detected in the KSHV-THP-1 cells. In addition, fewer than 10 transcripts were expressed at levels 
significantly greater than 100 times uninfected control cells (Figure 2B). Relative expression levels 
are depicted by heat maps comparing KSHV-THP-1 and THP-1 cells (Figure 2C).  Lytic transcripts 
detected at high to moderate expression levels likely reflects the low number of cells spontaneously 





























Figure 2: KSHV gene expression profile of KSHV-THP-1 cells.  (A) Analysis of log KSHV gene 
expression versus qPCR cycle-threshold (CT) value. Dotted line represents limit of detection for viral 
genes. (B) Cycle threshold (Ct) values for each KSHV open reading frame and the relative log fold 
change in gene expression in KSHV-THP-1 cells compared to uninfected THP-1 cells for each 
KSHV-specific primer pair.  (C) Heat map depicting KSHV transcription in KSHV-THP-1 compared 
to uninfected control for each open reading frame. Gene expression is represented as high (red), 











KSHV-infected THP-1 cells display nuclear LANA staining. 
To confirm KSHV infection of THP-1 cells, we performed immunofluorescence assays on 
KSHV-infected and uninfected THP-1 cells for LANA protein expression (Figure 3). Briefly, KSHV-
THP-1 or THP-1 cells suspended in PBS were spotted on slides, air-dried, and fixed with 
paraformaldehyde.  Cells were stained with an antibody directed against LANA followed by a 
TRITC-conjugated secondary antibody.  Cells were also stained with DAPI to demarcate the nucleus.  
As can be seen in Figure 3, uninfected THP-1 cells did not show any LANA staining while the 





















Figure 3: Expression of KSHV LANA by immunofluorescence staining in KSHV-THP-1 
compared to uninfected THP-1 cells. KSHV-THP-1 or THP-1 control cells were incubated with 
anti-LANA primary antibody followed by anti-RAT-TRITC secondary antibody. KSHV-THP-1 or 
THP-1 cells were incubated with DAPI followed by imaging using fluorescence microscopy. Images 










Primary infection of dendritic cells and macrophages has been shown to downregulate DC-
SIGN and, in B cells, infection decreased major histocompatibility complex class I (MHCI) (29, 30). 
Hence, we decided to investigate whether latently infected monocytes show a down regulation of 
monocyte activation markers. We found that surface expression of CD86 was reduced from 
approximately 31% in THP-1 cells compared to 4% for KSHV-THP-1 cells (Average fold change 
5.02 ± 2.4) (Figure 4). Additionally, we observed that surface expression of CD83 was downregulated 
from 12% to 1.20% in KSHV-THP-1 compared uninfected control cells (Average fold change 5.1± 
4.0).  Since KSHV-infected monocytes are prevalent in KS lesions, reduced expression of 
costimulatory molecules on the surface of antigen presenting cells such as monocytes during latency 
may dampen host immune responses against KSHV-infected cells.   
In order to confirm this, we performed RT-PCR for these markers as well as additional 
costimulatory markers CD80 and CD1a (Figure 5). We found that several genes associated with 
macrophage/dendritic cell activation were downregulated compared to uninfected THP-1 control cells 
including (Figure 5). We found that genes for costimulatory molecules CD80, CD86, CD1a and 
CD83 expression were downregulated 2.9, 8.1, 2.7 and 4.1 fold, respectively. The downregulation of 
CD86 and CD80 basal protein expression levels were confirmed in KSHV-THP-1 cells (Figure 5) by 








Figure 4: KSHV-THP-1 cells exhibit reduced CD86 and CD83 costimulatory molecule 
expression. (A) THP-1 or (B) KSHV-THP-1 cells were incubated with isotype control, CD86 or 
CD83 antibodies followed by anti-mouse-FITC conjugated secondary antibody. Cell surface 
expression of CD86 and CD83 compared to isotype control was analyzed by flow cytometry. 









Figure 5: Latent KSHV inhibits expression of costimulatory molecules. (A) qPCR analysis for 
expression of CD86, CD80, CD83, and CD1a in KSHV-THP-1 cells compared to uninfected THP-1 
control cells (B) Expression of CD86 and CD80 were determined by immunoblot in KSHV-THP-1 






We also investigated cytokine expression in KSHV-THP-1 cells compared to THP-1 controls 
by luminex multi-analyte analysis. Overall, we analyzed the expression of several cytokines and, for 
the most part, expression was unchanged (data not shown). However, a significance difference in 
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) was observed (Figure 6A). TNF-α and 
IL-1β expression levels were 7.73±0.56 and 4.90 ±0.59 pg/ml, respectively, in THP-1 cells and 
undetectable in KSHV-THP-1 cells. In order to confirm that these cytokines were downregulated at 
the transcription levels, we performed endpoint PCR. Figure 6B shows that transcription of both 
genes is suppressed in KSHV-infected THP-1 cells.  TNF-α and IL-β upregulate transcription of 
genes involved in inflammation, hematopoiesis and immune responses including costimulatory 






































Figure 6: Expression of select cytokines in KSHV-THP-1 cells. (A) TNF-α and IL-1β expression 
in THP-1 compared to KSHV-THP-1 cells was determined by multi-analyte luminex assay. Units 
shown are average pg/ml (B) KSHV-THP-1 (K) or THP-1 (T) cells were harvested and analyzed by 
PCR for gene expression of dowregulated transcripts TNF-α, IL-1β or GAPDH. Following PCR, 










 KSHV establishes a life-long persistent infection in the human host. The virus can establish 
latency in a number of different cell types including B cells, dendritic, epithelial and endothelial cells 
and monocytes. Although several studies have analyzed cellular and viral gene expression in lytically 
and latently infected B cells and endothelial cells (25, 27), here we report cellular and viral gene 
profiling of a latently infected monocytic cell line. In terms of viral gene expression, we observed that 
the KSHV-THP-1 cells predominantly expressed a latent viral gene profile with low levels of lytic 
replication, which we attribute to spontaneous reactivation.  We found that the KSHV-THP-1 cells 
display reduced expression of several cellular proteins involved inflammation and immunity as 
compared to uninfected cells. This suggests viral proteins may be downregulating expression of genes 
that could lead to detection of the virus by the host immune system.   
 KSHV specific cytotoxic T cell (CTL) responses are reduced in KS patients compared to 
KSHV-positive asymptomatic individuals, suggesting failure to mount a CTL-mediated immune 
response contributes to development of disease (16). After recognition of a T cell’s cognate antigen in 
the context of major histocompatibility complex (MHC) on the surface of antigen presenting cells 
(APCs), engagement of CD86 or CD80 on APCs provide a necessary costimulatory signal for CTL 
activation  (15, 33). Monocytes help dictate CTL action since they contribute to stimulation by 
upregulating costimulatory molecules such as CD80 and CD86 upon pathogen detection. 
Furthermore, monocytes are recruited to sites of T cell activation and are capable of differentiating 
into macrophages and dendritic cells, which are potent antigen presenting cells necessary for an 
effective cell mediated immune responses (14).   
Previous studies have shown that viral infection reduces expression of several cell surface 
immune receptors. Varicella-zoster virus (VZV) infection of mature DCs results in selective down-
regulation of expression of functional immune molecules, including MHC class I, CD80, CD83 and 
CD86 (23). Herpes simplex virus-2 (HSV-2) infection causes the down-regulation of MHC class I, 
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MHC class II, CD40, CD80 and CD86 on mature DCs (23), although HSV-1 infection of mature DCs 
only results in CD83 down-regulation (19). Human cytomegalovirus (HCMV) has been shown to 
down-regulate MHC class I, MHC class II, CD40, Cd80, Cd86, CD83 on monocytes-derived mature 
DCs generated by treatment with LPS and TNF-α (24, 28).  In addition, during acute HIV-1 infection 
lymphoid tissue has reduced CD80 and CD86 expression (21). KSHV infection of myeloid derived 
macrophages and dendritic cells results in a reduction in differentiation and antigen presentation to 
CTLs (9, 31).  Similarly, our study shows that KSHV latent infection of monocytic THP-1 cells leads 
to significant down-regulation of CD1A, CD80, CD83 and CD86. Thus, it seems that human viruses 
have multiple strategies to interfere with immune molecule expression in host cells, and our study 
indicates that KSHV has done this likewise. 
 During the infection process, KSHV deploys an evasion strategy to avoid immune 
surveillance and establish a persistent infection in the host. Thus, targeting the mechanisms by which 
KSHV evades host immunity, particularly during latency, will be critical in eliminating latent viral 
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 The coevolution of herpesviruses and humans has produced a relationship that, for most 
infected individuals, exists entirely behind the scenes with no obvious effects save for an occasional 
illness, which with proper treatment is not of serious concern. The majority of people who are 
infected by herpesviruses are asymptomatic. However, once infected by a herpesvirus, the virus will 
persist for the life of the individual. Consequently, although infection is an innocuous event, the tug-
of-war between virus and host that goes unnoticed is one of great struggle between the host’s ability 
to fight infection and the arsenal of evasion tactics employed by the virus to gain access and establish 
infection.  
 Human herpesviruses are divided into three subfamilies: alpha, beta and gamma. The newest 
member is Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8), which causes several 
malignancies including Kaposi’s sarcoma, an endothelial cell cancer, and two B-cell disorders, 
primary effusion lymphoma and multicentric Castleman’s disease (1, 11, 14, 50, 59). KSHV has a 
wide host-range of infection in that it is capable of infecting endothelial, epithelial, and B cells, 
monocytes as well as dendritic cells (2, 7, 8, 42, 43). Once infected, KSHV, as do all herpesviruses, 
traffics to the nucleus where it establishes latent infection. Life-long persistence is achieved through 
latent and lytic replication cycles. The former ensures the viral genome is passed to daughter cells 
during mitosis, and the latter is responsible for infection of naïve cells.  
 Both latent and lytic phases of the viral lifecycle present opportunities for the host immune 
system to detect KSHV infection. During latency, only a few viral transcripts are detected, which 
could serve as antigens for detection of virus infected cells by host immune cells. Moreover, lytically 
replicating virus expresses many proteins that could also serve as antigenic epitopes. The innate 
immune response immediately senses infection to slow down the infectious process by initiating 
secretion of antiviral cytokines, increasing synthesis of antiviral proteins and by activating the next 
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phase of the response. Adaptive or cell-mediated immunity is honed by a process called receptor 
editing to target virus-specific antigens expressed by antigen presenting cells. Once activated, cells of 
the adaptive response home in on and destroy infected cells. Both innate and adaptive responses allow 
for control of infection at each stage of the viral lifecycle. Hence, KSHV-associated disease normally 
arises in the context of an immunocompromised setting such as coinfection with HIV, advanced age 
or immune suppression therapy, in which case viral replication goes unchecked (46). At this point, 
viral replication may lead to cell proliferation, inhibition of apoptosis, and eventually tumorigenesis.  
 Reactivation from latency is a key event in the lifecycle of KSHV, which is preceded by 
external stimuli that are thought to trigger initiation of viral replication by activating cellular 
transcription factors that bind to the promoter elements of replication and transcription activator 
(RTA), the lytic switch protein of KSHV (33). RTA binds RTA-responsive elements in lytic 
promoters to induce immediate early gene expression. Lytic reactivation from latency is necessary to 
enable infection of naïve hosts, and this can be triggered by a number of signals from environmental 
stimuli such as microenvironment oxygen levels, cytokines, secondary viral infection and chemical 
inducers. In the laboratory setting, phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA/PMA) 
and histone deacetylase (HDAC) inhibitors are used to induce KSHV reactivation and virus 
replication (15, 19, 32). TPA treatment induces activation of AP-1 and SP1 transcription factors that 
bind and activate the RTA promoter, which is normally blocked by nucleosomes. HDAC inhibitors 
butyrate or trichostatin A also enable SP1 binding to the RTA promoter. The ability of KSHV to 
sense various cellular signals indicates KSHV has evolved mechanisms to sense environmental cues 
as a means to survive. For example, cellular stresses can result in release of hormones 
epinephrine/norepinephrine, which have been shown to reactivate KSHV via protein kinase A (PKA) 
pathway (13). Stress is a major factor for reactivation of varicella zoster virus (36), however, it would 
seem that these mechanisms for sensing stress may be utilized by KSHV as well. Cytokines, 
interferon-γ, HIV-infected T cell-derived hepatocyte growth factor, and oncostatin M can induce 
replication of KSHV in BCBL-1 cells (12, 38). The RTA promoter contains several hypoxia response 
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elements, suggesting hypoxic conditions, such as those found in the tumor microenvironment, may 
induce RTA expression (9). Indeed, research has shown that hypoxia-associated transcription factors 
HIF-1α and HIF-2α activated RTA (26). Finally, superinfection with KSHV or coinfection with other 
herpesviruses or HIV, for example, also initiates viral reactivation although the molecular 
mechanisms are unclear (37, 54).  
 Given coinfection with other herpesviruses or HIV can lead to KSHV reactivation (52, 54), 
we hypothesized that coinfection by the secondary pathogen was likely to activate an innate immune 
response. Hence, we asked whether the activation of a specific class of molecules called toll-like 
receptors (TLRs) resulted in reactivation of KSHV from latency. TLRs are a family of innate immune 
molecules that sense viral infection and initiate an antiviral state within the infected cell and local 
cellular environment by the secretion of autocrine and paracrine factors (29). Since a cell in which 
TLRs are activated is very likely to die from the immune response, it would seem advantageous for 
KSHV to want to escape. In the context of primary infection, we previously reported that KSHV 
stimulated TLR3 during primary infection of monocytes (58). Thus, we established that TLRs played 
a role in viral entry, however, nothing was known about latency. Moreover, it was unclear how the 
virus persisted if innate immunity was activated. The role TLRs played during latency was one aspect 
to my dissertation and developing a better understanding of the relationship between KSHV and the 
host immune response was the over-arching objective.  
 Since KSHV expresses several latent proteins that modulate TLR signaling, it was unknown 
whether TLRs could be activated in latently infected cells. Initially, transcriptional characterization of 
genes regulated by TLR activation was compared by qPCR array analysis between THP-1 acute 
monocytic-like cells and KSHV-infected THP-1 (KSHV-THP-1) cells that were treated with TLR 
agonists. In response to treatment with agonists specific to TLRs 4 and 8, we noticed increased gene 
expression in KSHV-THP-1 compared to THP-1 control cells. Although this result was unexpected 
since KSHV is known to inhibit interferon regulatory factors (IRFs) downstream of TLRs, we 
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hypothesized that TLR stimulation may lead to viral replication and, as a result, increased innate 
immune stimulation and greater changes in antiviral gene transcription.  
 This led us to test KSHV reactivation after treatment with a panel of TLR agonists in primary 
effusion lymphoma (PEL) cells, which are patient-derived B cell tumors harboring latent KSHV and 
are a more physiologically relevant cell line. First, since it was unknown which TLRs PEL cells 
expressed, we characterized the TLR expression profiles of two PEL cell lines: BCBL-1 and BC-3 
(2). TLR expression profiling revealed that these cell lines expressed the majority of TLRs and would 
be viable models to test our hypothesis. To examine KSHV reactivation, we stimulated BCBL-1 cells 
with TLR-specific agonists and measured KSHV DNA replication by qPCR. Initially, we discovered 
that only TLR8 activation was capable of inducing viral reactivation, which was comparable to levels 
induced by the positive control TPA, and this occurred up to four days post treatment with peak 
reactivation at 48hrs (25). The cognate ligand of TLR8 is single-stranded RNA. To determine 
whether this effect was specific to BCBL-1 cells or whether TLR8 could stimulate reactivation in 
other PEL cells, we tested three other lines, BC-3, BCP-1 and VG-1, and in each case TLR8 
activation led to reactivation. We demonstrated specificity by activating TLR8 with multiple TLR8-
specific agonists. We confirmed that TLR8 did indeed induce KSHV replication by performing RTA 
promoter luciferase reporter assays, measuring KSHV viral DNA replication and lytic gene and 
protein expression, and finally, determining whether infectious progeny virus was released by 
infecting naïve Vero cells with supernatants from TLR8-stimulated, reactivated PEL cells. 
Altogether, these data confirmed that TLR8 could signal to latent KSHV in some fashion to initiate 
viral replication, although the molecular details were not entirely clear.    
 The finding that TLR8 could mediate reactivation led us to ask what signaling components of 
the TLR8 pathway were necessary for reactivation. TLR8 downstream signaling diverges from the 
adaptor protein MyD88 to transcription factors NF-kB and IRF-7. NF-kB and IRF-7 upregulate 
proinflammatory cytokines and type I IFN, respectively. To explore the possibility of whether NF-kB 
or IRF-7 could modulate reactivation, we first determined that both pathways were activated in 
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response to TLR8 activation. We utilized immunoblotting, luciferase reporter assays and qPCR 
techniques to confirm that both arms of the TLR8 pathway were activated in PEL. IkBα, which binds 
and inhibits NF-kB nuclear translocation, is degraded after TLR8 stimulation enabling NF-kB 
trafficking to the nucleus, and we showed that IkBα was degraded in PEL cells stimulated with TLR8 
agonists. Moreover, using an NF-kB reporter assay, NF-kB promoter activity was increased 7-fold 
compared to mock treatment, again indicating NF-kB was activated. In two PEL cell lines, BCBL-1 
and BC-3, IFN-α and IFN-β transcription was upregulated several hundred fold compared to mock 
treated cells in response to TLR8 stimulation, indicating IRF-7 was also active. This was confirmed 
by immunoblot for IRF-7 expression, which is upregulated in an auto-feedback mechanism. Although 
both pathways were activated, it was possible that reactivation was dependent on one arm of the 
pathway, independent of the other. Thus, to test this hypothesis, we treated PEL cells with TLR8 
agonists and either control or Bay11-7082, an NF-kB specific pharmacological inhibitor that blocks 
IkBα degradation (40). Treatment with Bay11-7082 had a negligible effect on KSHV reactivation, 
suggesting that reactivation was not dependent on NF-kB. This also suggested IRF-7 was responsible 
for reactivation, unless an uncharacterized pathway downstream of TLR8 was required. An IRF-7 
dominant negative (IRF-7DN) construct was obtained to test the role of IRF-7 in TLR8-mediated 
reactivation. Transfection of IRF-7DN into BCBL-1 cells followed by stimulation of TLR8 resulted 
in near complete ablation of reactivation compared to vector control, as measured by immunoblot for 
the lytic protein vIL-6. The result that TLR8-dependent reactivation was dependent on IRF-7 is 
controversial since IRF-7 has also been shown to compete with RTA for transactivation on viral 
promoters to suppress viral gene expression as a mechanism of silencing lytic gene expression (56). 
However, this was only shown for the lytic gene promoter Orf57. Thus, our results may suggest 
disparate roles for IRF-7 depending on the context of the viral lifecycle, i.e., lytic versus latent.  
 In mammals, TLRs 7 and 8 are capable of sensing single-stranded RNA, and while our data 
suggested a significant role for TLR8 in reactivation, experiments with synthetic TLR7 agonists as 
well as the natural redundancy of these receptors suggested TLR7 could also have an effect on KSHV 
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reactivation. To address this possibility, we generated BCBL-1 cell lines in which either TLR7 or 
TLR8 were stably knocked-down by introduction of short-hairpin RNAs. We found that while a 
minor role for TLR7 was plausible, TLR8 was responsible for the majority of signaling and KSHV 
reactivation. One caveat to these experiments was the use of single-stranded poly-uridine to 
stimulated TLRs 7 and 8, which is more specific for TLR8 compared to TLR7. Thus, while it appears 
TLR8 is more important, a role for TLR7 could not be ruled out.  
 Since our results up to this point were obtained with the use of synthetic TLR agonists, we set 
out to determine whether activation of TLR7/8 with a physiological relevant virus would lead to 
reactivation. Therefore, we utilized vesicular stomatitis virus (VSV), a single stranded RNA virus 
known to activate TLR7/8 through endocytosis and which can infect human B cells, to translate our 
results to live virus infections (34). At 0.1 and 1.0 multiplicities of infection, we observed at 24h and 
48h post-infection that VSV induced reactivation of KSHV from latency, in agreement with our 
results.  
 Taken together, our data suggests that KSHV has evolved to sense the cellular milieu during 
latent infection. TLR7/8 activation is sensed thereby leading to viral reactivation, survival and 
propagation. Interestingly, TLR7/8 can also sense endogenous RNA from necrotic events, which 
otherwise would not be available for TLR7/8 activation (3). This work also opens up the possibility 
that viruses that can activate TLR7/8 such as HIV or dengue virus for example, may lead to 
reactivation and presents a potential mechanism for secondary infections that induce reactivation. 
 Next, we characterized a role in blocking inflammasome-dependent innate immune responses 
for KSHV lytic protein Orf63, which prior to our work did not have an assigned function but was 
known to localize to the tegument of the virion (44). A KSHV wide analysis of viral protein-protein 
interactions using yeast two-hybrid and coimmunoprecpitation approaches revealed that Orf63 
interacted with another tegument protein Orf64, in addition to a number of other proteins that interact 
with Orf64. This suggested that Orf64 may be important in recruiting viral tegument proteins for 
virion assembly. Orf64 was characterized by our lab as a viral deubiquitinating enzyme (DUB), 
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however, this function may be independent of any interaction with Orf63 or it could play a role in the 
pro-viral function of Orf63. 
 Tegument proteins are known to be able to function in diverse ways in addition to their 
structural roles, e.g., viral replication, capsid transport to and from the nucleus, regulation of 
transcription, translation, apoptosis and immune modulation (30). Homologs of Orf63 are found 
across each subfamily of human herpesvirus, with HSV-1 expressing UL37, HCMV encoding UL47 
and BOLF1 as the EBV homolog. In HSV-1, UL37 is essential for viral growth and it has been 
characterized as playing a role in secondary envelopment of the virion as well as regulation of viral 
transcription. UL37 also interacts with TRAF6 leading to activation of NF-kB signaling, which is 
thought to regulate expression of ICP0, but also may affect NF-kB responsive genes. Interestingly, we 
have seen Orf63 activate NF-kB promoter activity in luciferase assays after overexpression of Orf63, 
suggesting this function may be conserved across virus subfamilies (data not shown). Moreover, 
knockout of the Orf63 homolog in MHV-68 results in a replication dead virus (49). Currently, 
nothing is known regarding the function EBV BOLF1 and very little for HCMV UL47. In human 
foreskin fibroblasts, UL47 coimmunoprecipitated with several tegument proteins and the major 
capsid protein (4). Moreover, virus lacking UL47 was less infectious and exhibited delayed viral 
immediate early transcription that was not attributed to an entry defect, suggesting UL47 is involved 
in immediate early transcription in addition to its role as a scaffolding protein in the tegument.  
 Using bioinformatics programs CLUSTALW and BLASTP, we found that KSHV Orf63 was 
homologous to the NBD and LRR domains of NLRP1, a member of the NLR family of innate 
immune sensors (24). This suggested Orf63 functioned as an inhibitor of NLRP1 since Orf63 also 
lacked the PYD and CARD effector domains required for signal transduction. We generated 
lentivirus encoding Orf63 in order to infect THP-1 cells to create a cell line to test NLR innate 
immune responses and in which Orf63 was constitutively expressed. Treatment of THP-1-Orf63 cells 
with the NLRP1 agonist MDP resulted in significantly less bio-active IL-1β and IL-18, as indicated 
by ELISA and immunoblotting, and protected cells from NLRP-1-induced cell death. We confirmed 
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that Orf63 was a potent inhibitor of NLRP1 by performing NLRP1 inflammasome reconstitution 
assays, which allow us to specifically address NLRP1 activity compared to the THP1 model, where 
non-specific activation with MDP could occur. The reconstitution model also allowed us to more 
specifically address caspase-1 enzymatic activity, which was also inhibited by Orf63. Our results also 
suggested that Orf63 may act upstream of caspase-1, in contrast to several previously characterized 
viral inhibitors of inflammasomes, notably the poxvirus crmA proteins that block caspase-1 activity 
directly.  
 The homology between Orf63 and NLRP1 led us to believe that Orf63 would likely interact 
with NLRP1 since NBD and LRR domains have been shown to mediate homo- and hetero-typic NLR 
interactions (18, 35). We tested by immunoprecipitation whether this interaction could occur and 
indeed we observed that Orf63 and NLRP1 specifically interacted in both directions. We confirmed 
this result by showing Orf63 could interact with endogenous NLRP1 in THP-1 cells. It remained 
possible that Orf63 interacted with the components of the NLRP1 inflammasome, ASC and 
procaspase-1. We demonstrated that no interaction between ASC or procaspase-1 and Orf63 
occurred, and to discern the minimal components required for interaction as well as show ASC and 
caspase-1 were unnecessary, we performed coimmunoprecipitations using purified Orf63 and NLRP1 
protein and found that these proteins alone facilitated an interaction. Using a panel of NLRP1 
mutants, it was shown that the central NBD domain was necessary for interactions with NLRP1. 
Moreover, in the absence of the NLRP1 LRR, the interaction was enhanced, suggesting Orf63 
mimicked the LRR of NLRP1, which binds the NBD of NLRP1 in an autoinhibited state in the 
absence of ligand. On the other hand, we generated Orf63 constructs containing a truncated viral 
NBD and an LRR with a small segment of the NBD and found both sufficiently inhibited NLRP1 
activity as well as interacted with NLRP1. While we were not able to define the minimal genetic 




 Poxvirus vPOP proteins are homologous to ASC, a crucial adaptor for the function of several 
NLR sensors, and in theory enables vPOP to inhibit NLRs that utilize ASC (21, 28). This activity 
would not prevent activation of NLRs that function in non-inflammasome capacities through other 
adaptors or for NLRs that can form inflammasomes in the absence of ASC such as NLRP1. 
Immunoprecipitation of NLRP1, ASC and procaspase-1 with Orf63 or vector control showed that 
Orf63 disrupted the ability of NLRP1 to interact with procaspase-1, and not ASC. It was also shown 
by size-exclusion chromatography that Orf63 prevented NLRP1 oligomerization, a necessary event in 
inflammasome formation. Thus, this proves that Orf63 has targeted NLRP1 directly to prevent the 
formation of the inflammasome itself and bypasses any limitation presented by targeting only ASC-
NLR interactions.  
 By definition, inflammasomes convert inactive proIL-1β and proIL-18 into biologically 
active forms that possess antiviral properties (41). IL-1β and IL-18 proinflammatory cytokines 
secreted from an infected cell could upregulate proinflammatory cytokines in bystander cells through 
ligation of the IL-1 or IL-18 receptor, respectively, and activation of downstream NF-kB responsive 
genes (53). Orf63 is present in the virion during infection and is synthesized de novo during 
reactivation. Therefore, Orf63 could inhibit inflammasome activation at each stage of the viral 
lifecycle. If Orf63 were required for blocking NLRP1 during infection, knockdown of Orf63 
expression during primary infection should result in an increase in IL-1β and or IL-18. In primary 
human monocytes infected with KSHV, when Orf63 expression was silenced by siRNA, we observed 
approximately a two-fold increase in secreted IL-1β, in agreement with our hypothesis. Absence of 
Orf63 also had deleterious effects on viral transcription, with several lytic transcripts almost 
undetected. The importance of Orf63 in the KSHV lifecycle is not limited to de novo infection. 
Transcriptional silencing of Orf63 during reactivation of latent KSHV also impaired virus replication 
and production of progeny virus and resulted in increased IL-1β secretion, confirming that Orf63 
functions to inhibit the NLRP1 inflammasome at each viral lifecycle stage and its absence results in 
an inflammatory response that is capable of blocking viral replication. Evidence to support an 
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antiviral role for NLRP1 in modulating KSHV reactivation was demonstrated by knocking down 
NLRP1 in PEL cells and inducing KSHV reactivation, which resulted in higher levels of viral DNA 
replication and production of progeny virus. Thus, NLRP1 appears to be important in limiting KSHV 
reactivation, and possibly de novo infection, while Orf63 is encoded by the virus to suppress NLRP1 
and promote infection.  
 Our analysis up to this point strongly supported a role for Orf63 as a bonafide inhibitor of 
NLRP1. However, since NBD and LRR domains are conserved across all NLR family members, it 
remained possible that Orf63 could interact with additional NLR proteins. NLRP3 is the most well 
characterized inflammasome-forming NLR, capable of sensing viral, bacterial and fungal infection as 
well as endogenous ligands (45). NLRP3 requires interactions with ASC for activation of caspase-1 
and IL-1β and IL-18. Using THP-1-Orf63 cells, we stimulated NLRP3 with several cognate ligands 
and found that Orf63 potently inhibited NLRP3 in response to each ligand, suggesting Orf63’s 
activity was not limited to the NLRP1 inflammasome. Subsequently, we showed that NLRP3 
interacted with Orf63 by immunoprecipitation and in-vitro pull-down experiments. Orf63 could also 
interact with several other NLRs, however, we did not detect an interaction with NOD1. Although 
Orf63 is promiscuous in its ability to bind NLRs, from an evolutionary standpoint this is logical as the 
virus has limited coding capacity and would not want to express multiple NLR inhibitors. In other 
words, the ability of one protein to inhibit multiple cellular proteins is more efficient. This also opens 
up the possibility that other NLRs may have antiviral roles in the KSHV lifecycle and warrants 
further exploration. Moreover, NLRs are implicated in antiviral roles independent of the 
inflammasome and not all NLRs form inflammasomes, which may point to functions for Orf63 in a 
non-inflammasome capacity. Finally, Orf63 may function in regulating viral transcription or could 
promote transcription of cellular genes, functions ascribed to Orf63’s herpesviral homologs. These 
putative characteristics of Orf63 remain to be investigated.  
 In chapter 4, we characterized a defect in host adaptive immunity that arises as a result of 
latent KSHV infection in monocytes.  Costimulatory molecules are critical for T cell activation, 
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regulation and tolerance, and dampening of T cell responses. The correct activation of costimulatory 
pathways is important for immune responses to viruses, bacteria and even cancerous cells, as well as 
required for appropriate tissue grafts and autoimmune disorders (47). Costimulatory molecules CD86 
and CD80 surface expression on APCs such as monocytes, macrophages, and B cells is upregulated 
after infection and stimulation of cellular PRRs (6, 48). Both type I and II interferon, as well as IL-4, 
vascular endothelial growth factor (VEGF) and tumor necrosis factor-α (TNF-α) can upregulate 
expression of costimulatory molecules. These cytokines are typical inflammatory mediators of PRR 
activation. Along with upregulation of costimulatory molecules, inflammatory cytokines and 
chemokines recruit T cells to sites of inflammation, where CD28 on the surface of the T cell engages 
either CD80 or CD86 along with cognate MHC:TCR interactions to promote adaptive immunity (57). 
CD80 and CD86 also bind CTLA4, the negative regulator of T cell immunity, to ensure T cell 
responses do not result in excessive cell killing. In fact, the interaction between CD80/86 and CD28 is 
much weaker than CTLA4.  
 Our work demonstrates that KSHV expresses a latent factor capable of modulating 
costimulatory molecule expression, and therefore would suppress T cell immunity against latent viral 
antigens. Initially, by genome wide analysis of cellular expression, we found that KSHV suppressed 
the expression of several thousand cellular genes greater than two-fold compared to control cells, a 
significant feat given only a few latent viral proteins are known to be expressed by KSHV. A few of 
the most significant genes were those involved in host immunity including transcription of cytokines 
with the capacity to modulate costimulatory molecule expression such TNF-α and IL-1β. By 
immunoblot and flow cytometry analyses, we showed that CD86, CD83, CD1a, and CD8 are 
suppressed by KSHV in monocytes during latency. The research presented in chapter 4 proposes 
another model by which KSHV suppresses cytotoxic T cell responses. 
It is known that KSHV lytic proteins K5 and K3 can downregulate expression of CD80 and 
CD86 as well as MHC class I through ubiquitination and endosomal degradation, and this activity is 
important in impairment of B and T cell interactions and detection by NK cells (17, 39). It has been 
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proposed that vIRF-1 and K3 in some cell types are expressed during latency, but this hasn’t been 
confirmed (16, 20, 51). vIRF-1 can inhibit MHC class I expression by interacting with CBP and 
blocking IRF-1 and NF-kB-dependent upregulation of MHC class I (31). The mechanism(s) by which 
CD80 and CD86 are blocked in KSHV-THP-1 cells is not clear. vIRF-1 expression is detected in 
KSHV-THP-1 cells at high levels, which suggests its NF-kB blocking ability may also regulate CD80 
and CD86 expression, which are also regulated by NF-kB (60). The role vIRF-1 and K3 play during 
latency in these cell types should be investigated in future experiments. Our work demonstrates 
potential for therapeutic targeting of the mechanisms by which KSHV usurps host immunity to 
facilitate detection and elimination of latent KSHV.  
The primary goal of my dissertation was to gain a greater understanding of the relationship 
between KSHV and host immunity in an effort to elucidate molecular mechanisms of viral 
pathogenesis and potentially reveal insight into new avenues of research exploiting these findings. 
We have characterized a key signaling pathway utilized by KSHV in PEL cells that enables virus 
replication, survival and persistence, and which presents a potential method to target reservoirs of 
latent virus. In addition, we uncovered a mechanism by which KSHV inhibits NLR signaling 
pathways through the expression of Orf63, further revealing that viral tegument proteins are more 
than just scaffolding proteins for virion architecture, but rather they likely mediate key processes 
during viral entry and egress. The preliminary evidence for immune modulation in APCs for KSHV 
necessitates exploration into the mechanism of suppression of costimulatory molecules in monocytes, 
and offers the possibility that latent antigens of KSHV could be recognized by the host if the 
mechanism is disrupted.  
Furthering our understanding of the relationship between KSHV and immune system is 
necessary for potentially exploiting vulnerabilities in viral defenses to block infection and potentially 
tumorigenesis. By uncovering pathways critical for virus survival we reveal future strategies for drug 
design. For instance, work presented within raises the possibility that targeting latent KSHV could be 
achieved through stimulation of TLR 7/8, which would reactivate the virus exposing antigenic lytic 
 180 
 
epitopes. Indeed, our work was unknowingly performed concomitantly with a phase-1 clinical trial 
using a topical imiquimod cream to treat classic or endemic KS in HIV-negative patients (10). 
Furthermore, a later report showed a clinical response to topical imiquimod for treatment of classic 
KS of the leg, and another report showed clinical remission of classic KS with topical imiquimod (5, 
22). Imiquimod is a member of a family of low molecular weight synthetic compounds called 
imidazoquinolines, which are capable of activating an immune response through TLR 7/8 and has 
been shown to have antiviral properties, specifically against human papillomavirus and herpes 
simplex (27, 55). Our work suggests that imiquimod may be reactivating latent KSHV in KS lesions 
enabling a local inflammatory response targeting KSHV. It is important to note that these patients had 
intact immune systems and that this therapy would not be advised in immunologically incompetent 
individuals. However, treatment of KS patients with imiquimod and a viral replication inhibitor may 
enable elimination of KSHV without the need for immunological clearance. Several questions remain 
to be answered regarding TLR 7/8-dependent reactivation of KSHV. We demonstrated that TLR7/8 
stimulation induces KSHV reactivation in PEL cells, however, it needs to be demonstrated whether 
this applies to all cell types that harbor latent KSHV. Furthermore, TLR 7/8 reactivates KSHV in B 
cells, but another cell type may express an alternate TLR profile and respond differently, which could 
have different effects on viral latency. The first cell type to investigate would be KSHV-infected 
endothelial cells since this cell type would be more physiologically relevant and more broadly 
applicable compared to PEL. Preliminary evidence indicates that KSHV-infected endothelial cells 
express a different repertoire of TLRs compared to uninfected controls (unpublished results), 
suggesting KSHV modifies the cellular TLR expression profile, presumably for its benefit. Also, 
since these studies were small in nature and designed to address toxicity issues, of which there were 
few, a larger randomized, placebo controlled study designed to address efficacy is warranted. And 
while additional questions remain, these results nevertheless demonstrate a potentially promising 
translational link between in-vitro and clinical results. 
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Our work on Orf63 shed light on several emerging paradigms regarding herpesvirus tegument 
proteins, namely that these proteins are more than just scaffolding molecules involved in the structure 
of the virion, but rather provide a payload of proviral factors at the onset of infection in the absence of 
viral protein synthesis. The discovery of Orf63 also suggests that other herpesviruses encode NLR 
inhibitors and that NLRs may mediate antiviral responses to herpesviruses. Moreover, they represent 
new targets of potential therapeutic drugs designed to block tegument protein activity. Murine 
herpesvirus lacking Orf63 is replication incompetent (49) and likely unable to block NLR-dependent 
innate immune responses, and if Orf63 exhibits activity similar to its herpesvirus homologs, it may 
also be unable to mediate transcription of immediate early genes. As with other herpesviral proteins, 
it is highly likely that Orf63 has additional functions. The non-NLR role(s) Orf63 has during infection 
remains unknown and future work to explore this putative function is necessary. In addition, several 
questions remain regarding its role in NLR inhibition. What is the minimal protein structure of Orf63 
necessary for its anti-NLR function? If a small Orf63 peptide is sufficient for blocking NLRs, this 
smaller unit would be easier to commercially produce for therapeutic options, and be less 
immunogenic and costly.  In addition, since Orf63 has broad activity against NLRs, it will be of 
interest to determine whether Orf63 is a pan-NLR inhibitor. Nonetheless, given the essential nature of 
Orf63, it represents a viable target to inhibit virus entry or assembly. Since NLRs are associated with 
many human diseases such as cancer, inflammatory and autoimmune disorders, this work also opens 
up the possibility of utilizing Orf63 as a therapeutic agent to inhibit NLR-dependent inflammation.  
Reactivation of KSHV by stimulation of TLR 7/8 leads to more lytic antigens that could be 
recognized by the host immune system. However, reactivation also upregulates any 
immunomodulatory lytic protein expressed by KSHV. Hence, any strategy to utilize immunologic 
recognition of KSHV during viral replication regardless of trigger must also address this issue. We 
have described that KSHV actively suppresses the costimulatory molecules required for an efficient 
immune response in monocytes during latency. We know of at least three viral proteins, vIRF-1, K3 
and K5 that are capable of suppressing adaptive immunity during lytic replication. In the future it will 
 182 
 
be necessary to determine what latent proteins also mediate suppression. Reports indicate that vIRF-1 
may be expressed during latency, which could partially explain the effect, however, this remains to be 
fully investigated (20, 23). Indeed, we observed vIRF-1 expression in our latently infected 
monocytes, and experiments addressing vIRF-1 and costimulatory molecules during latency in these 
cells should be explored. Inhibiting vIRF-1 during latency may return costimulatory molecule 
expression to basal levels for proper upregulation in response to an immune stimulus. For example, 
how latently infected monocytes respond to activators of innate immunity such as TLR agonists is 
important to investigate to determine whether a defect in antipathogen innate responses is translated 
into defective adaptive responses. Removing the block to immune recognition of virus at both latent 
and lytic stages will be critical in obtaining adequate immunity to KSHV infection.  
In summary, we hope that the work described here, while investigating several previously 
unknown aspects of KSHV biology, serves to stimulate future research addressing questions raised in 
these discoveries, and leads the field one step closer to uncovering a cure for KSHV infection and its 
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